WO2001090091A1 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 - Google Patents

Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Download PDF

Info

Publication number
WO2001090091A1
WO2001090091A1 PCT/SE2001/001156 SE0101156W WO0190091A1 WO 2001090091 A1 WO2001090091 A1 WO 2001090091A1 SE 0101156 W SE0101156 W SE 0101156W WO 0190091 A1 WO0190091 A1 WO 0190091A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
thiazol
acetyl
tmazol
chloro
Prior art date
Application number
PCT/SE2001/001156
Other languages
French (fr)
Other versions
WO2001090091A8 (en
Inventor
Tjeerd Barf
Marianne Nilsson
Guido Kurz
Jerk VALLGÅRDA
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to AU6445601A priority Critical patent/AU6445601A/en
Priority to NZ522507A priority patent/NZ522507A/en
Priority to US10/276,954 priority patent/US7125900B2/en
Priority to IL15267001A priority patent/IL152670A0/en
Priority to EP01938885A priority patent/EP1283833A1/en
Priority to CA002408142A priority patent/CA2408142C/en
Priority to JP2001586279A priority patent/JP2003534337A/en
Publication of WO2001090091A1 publication Critical patent/WO2001090091A1/en
Publication of WO2001090091A8 publication Critical patent/WO2001090091A8/en
Priority to NO20025587A priority patent/NO323779B1/en
Priority to US11/511,224 priority patent/US20060287374A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (ll ⁇ HSDl).
  • glucocorticoids have a central role in diabetes, e.g. the removal of the pituitary or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and F.D.W. Leukins (1936) J. Exp. Med. 63: 465- 490; Houssay, B.A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
  • Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetic, and omental fat appears to be of central importance.
  • Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000).
  • Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e. reduced central obesity (Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: 1210-1213).
  • Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 1 l ⁇ HSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C et al. (1998) Science, 280: 1378-1383).
  • glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin.
  • 1 l ⁇ HSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess.
  • Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., S.L. Cheng, and G.S. Kim (1999) J. Endocrinol. 162: 371-379).
  • the negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of ll ⁇ HSDl in the glucocorticoid effect (Bellows, C.G., A. Ciaccia, and J.N.M. Heersche, (1998) Bone 23 : 119-125).
  • WO 99/65884 discloses carbon subtituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may e.g. be used against cancer, inflammation and arthritis.
  • US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof.
  • US 5,403,857 discloses benzenesulfonamide derivatives having 5-li ⁇ oxygenase inhibitory activity.
  • tefrahydrot azolo[5,4-c]pyridines are disclosed in: Analgesic tetiahydrothiazolo[5,4-c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465.
  • FR 2384498 discloses thiazolo-benzenesulfonamides which show antibacterial, antifungal and hypoglycaemic properties.
  • WO99/28306 and EP 0 819 681 A2 relate to t azolobenzenesulfonamides which can be used for treating neurodegenerative pathologies, such as Alzheimer's disease.
  • JP 7149745 A2 and JP 7149746 A2 both describe 2-aminothiazole derivatives as esterase inhibitors. None is disclosed about inhibiting ll ⁇ HSDl.
  • JP 7309757 A2 relates to treating Alzheimer's disease using N- (5-nitio-2-thiazolyl)benzenesulfonamides.
  • JP 3173876 A2 presents preparation of diphenylthiazoles. These compounds are used as anti-inflammatories, analgesics, anti- allergy agents, uric acid accelerators and blood platelet aggregation inhibitors.
  • EP 0 790 057 Al discloses an antibacterial or bactericide comprising a 2-aminothiazole derivative.
  • US 2 362 087 describes the preparation of thiazolobenzenesulfonamides, such as 2-bromobenzenesulfonamido-4-methylthiazole. Notiiing is disclosed about iiihibiting ll ⁇ HSDl and no therapeutic use of such substances is disclosed.
  • the compounds according to the present invention solve the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11- ⁇ -HSDi), and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and depression.
  • 11- ⁇ -HSDi human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme
  • One object of the present invention is a compound of the formula (I)
  • T is a monocyclic aryl ring or monocyclic heteroaryl ring, optionally independently substituted by [R] n , wherein n is an integer 0-5, and R is hydrogen, C ⁇ - 6 -alkyl, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
  • A is Ci- 6 -alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
  • B is hydrogen, methyl, ethyl, n-propyl, n-butyl, halogenated C ⁇ -6-alkyl, - 6 -acyl or . -alkoxycarbonyl; as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
  • T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
  • A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3-(ethyl 3-methylbutanoate);
  • B is selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, 2,2,2-trichloroethyl, acetyl and carbethoxy.
  • T is a substituted phenyl group
  • phenyl ring is substituted as follows:
  • T is phenyl, wherein the phenyl is substituted with one or more of 3-chloro- 2-cyanophenoxy, fluoro, phenyl, n-propyl and, in o- or m-position, bromo, chloro, methyl; b) T is phenyl substituted with at least two chloro and optionally one or more methyl; or
  • T is phenyl substituted with one bromo and 2 fluoro.
  • Another object of the present invention is a compound as described above for medical use.
  • Another object of the present invention is a process for the preparation of a compound as described above comprising at least one of the following steps: a) sulfonamide coupling by reacting a 2-aminothiazole with a sulfonylchloride in the presence of a base, b) sulfonamide coupling by reacting a 2-aminothiazole derivative with a sulfonylchloride in the presence of a base, c) saponification by treatment of a carboxylic acid ester with aqueous hydroxide, d) amide coupling by reacting a carboxylic acid with an amine in the presence of
  • EDCI e) formation of a thiazole ring by reacting an optionally substituted thiourea with an ⁇ -haloketone, f) formation of a thiazole ring by reacting a thiourea with a ketone, g) reduction of an ester with lithium aluminium hydride, h) conversion of an alcohol to a bromide with triphenylphosphine and carbon tetrabromide, i) elimination of a bromide with a base to an alkene.
  • Another object of the present invention is a method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and mflammatory disorders, said method comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound of the formula (I)
  • T is an aryl ring or heteroaryl ring, optionally independently substituted by [R] mention, wherein n is an integer 0-5, and R is hydrogen, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
  • A is C ⁇ - 6 -alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
  • B is hydrogen, halogen, C ⁇ - 6 -alkyl, halogenated C ⁇ - 6 -alkyl, Ci-e-acyl or C ⁇ - 6 - alkoxycarbonyl; as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
  • These compounds may also be used in the manufacture of a medicament for the prevention, management or treatment of diabetes, syndrome X, obesity, glaucoma, hyperHpidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.
  • T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
  • A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3 -(ethyl 3-methylbutanoate);
  • B is selected from hydrogen, bromo, methyl, ethyl, n-propyl, n-butyl, 2,2,2- trichloroethyl, acetyl and carbethoxy.
  • Another object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound of the formula (I) as defined above, and a pharmaceutically acceptable carrier.
  • the compounds according to the present invention may be used in several indications which involve 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme.
  • the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis E 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical Endocrinology and Metabolism, 81, 3441-3447) and may also be used disorders in the immune system (see Franchimont et al, "Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes", The journal of Immunology 2000, Feb 15, vol 164 (4), pages 1768-74) and also in the above listed indications.
  • aryl in the present description is intended to include aromatic rings (monocychc or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph; a monocyclic ring) and naphthyl (a bicyclic ring), which optionally may be substituted by Ci-e-alkyl.
  • substituted aryl groups are benzyl and 2-methyl ⁇ henyl.
  • heteroaryl means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium.
  • heteroaryl rings examples are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cmnoline, quinazoline, indple, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3- benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane,
  • Examples of monocyclic heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiaz le, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, and tetrazole.
  • C ⁇ _6 ⁇ alkyl in the compound of formula (I) according to the present apphcation is preferably Ci-4-alkyl.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, hexyl, and isohexyl.
  • C i-.6-alkoxy in the compound of formula (I) according to the present application may be straight or branched, is preferably C ⁇ _4-alkoxy.
  • Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy.
  • C ⁇ _6-acyl in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C ⁇ _4-acyl.
  • exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3- butenoyl), hexenoyl (e.g. 5-hexenoyl).
  • halogen in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • prodrug forms in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-15).
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, ftm aric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.
  • Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like.
  • compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient.
  • the therapeutic composition is not immunogenic when administered to a human patient for therapeutic purposes, unless that purpose is to induce an immune response.
  • the preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
  • the active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • Adjuvants may also be present in the composition.
  • aqueous carriers are well known in the art.
  • exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
  • aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes.
  • Liquid compositions can also contain liquid phases in addition to and to t e exclusion of water.
  • additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
  • compositions comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • the preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
  • Other routes which are known for the skilled person in the art are thinkable.
  • compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrohdone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant e.g.
  • Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g.
  • non-aqueous vehicles which may include edible oils, e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • edible oils e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol
  • preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • a pharmaceutical composition according to the present invention may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition.
  • a weight percent is a ratio by weight of total composition.
  • 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition.
  • a suitable daily oral dose for a mammal, preferably a human being may vary widely depending on the condition of the patient. However a dose . of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
  • compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier.
  • the compounds of the present invention in labelled form may be used as a diagnostic agent.
  • the compounds of the formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in-vitro was studied using the following reagents and methods.
  • [1, 2(n) - H]-cortisone was purchased from Amersham Pharmacia Biotech.
  • Anti- cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech.
  • NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma.
  • the human 11- ⁇ -hydroxysteroid dehydrogenase type-1 enzyme (11- ⁇ -HSD was expressed in Pichiapastoris.
  • 18- ⁇ -glycyrrhetinic acid (GA) was obtained from Sigma.
  • the 11- ⁇ -HSDi enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 ⁇ L and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 ⁇ M), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 ⁇ M). Reactions were initiated by the addition of human 11- ⁇ -HSD t , either as Pichiapastoris cell homogenate or microsomes prepared from Pichiapastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL).
  • the plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting.
  • the amount of [ 3 H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter.
  • the calculation of the Kj values for the inhibitors was performed by use of Activity Base.
  • the K; value is calculated from IC 50 and the K m value is calculated using the Cheng Prushoff equation (with reversible inhibition that follows the Michaelis-Menten equation):
  • Kj IC 50 (l+[S]/K m ) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108].
  • the IC 50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance.
  • the Ki values of the compounds of the present invention for the 11- ⁇ -HSDl enzyme he typically between about 10 nM and about 10 ⁇ M. Illustrative of the invention, the following Ki values have been determined in the human 11 - ⁇ -HSDl enzyme assay (see Table 1):
  • Table 1 Ki values determined in the human 11- ⁇ -HSDl enzyme assay.
  • Reverse phase preparative HPLC was carried out on a 100 x 21.2 mm, 5 ⁇ Hypersil Elite column eluting with a gradient of 5% ACN in 95% water to 95% ACN in 5% water (0.2% TFA buffer) over 10 mins at a flow rate of 20 mL / min with the UV detector set at 254 nm.
  • Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Electrospray MS spectra were obtained on a Micromass platform LCMS spectrometer.
  • DIEA N,N- ⁇ isopropylethylamine
  • DMAP 4-dimethylammopyridine
  • EDCI l-(3- ⁇ methylan_ ⁇ mo ⁇ ro ⁇ yl)-3-ethylc ⁇ bodhmide hydrochloride
  • EDTA ethylene&aminetetraacetic acid
  • HOAT l-hydroxy-7-azabenzotriazole
  • HOBT 1-hydroxybenzotriazole hydrate
  • THF tetiahydrofuran SULFONAMIDE COUPLINGS: .
  • the carboxylic acid was suspended in DCM (0.05M) followed by the addition of EDCI (1.1 eq), triethylamine (3 eq), DMAP (0.5 eq) and the amine of choice (1.2 eq). DMF was added when the starting materials did not dissolve properly. The reaction mixture was stirred at ambient temperature over night. The organic phase was washed with aqueous HC1 (1 M), dried over sodium sulfate, filtered and evaporated in vacuo. The crude product amide was purified by flash column chromatography on sihca gel, eluting with methanol (1— 3— »6%) in DCM or ethyl acetate.
  • the title compound was prepared according to METHOD A from 4-methyl-5-(2,2,2- tricMoroe yl)-l,3-tMazol-2-ylamine (123 mg, 0.5 mmol, prepared according to Dodinov, A.A et al (1993) Chem. Heterocycl. Comp (Eng. Transl.) 29(8): 955-958) and 2,4,6-trichlorobenzenesulfonyl chloride (140 mg, 0.5 mmol). The solution was allowed to stand at room temperature overnight.
  • the title compound was prepared from 5-acetyl-2-a ⁇ mo-4-methylthiazole and 4-n- propylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a white sohd (11.6 mg) with purity >90%: MS (pos) m/z 339.2; HRMS m/z 338.0748 (calc. of monoisotopic mass for C 15 H 18 N 2 ⁇ 3 S 2 gives 338.0759).
  • the title compound was prepared from 5-acetyl-2-a ⁇ o-4-methylthiazole (42 mg) and 4-bromo-2,5-d fluorobenzenesulfonyl chloride (79 mg) as described in the synthetic METHOD B to give a white solid (21.0 mg) with purity >90%: MS (pos) m/z 411.2, 413.2.
  • This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 4-biphenylsulfoiryl chloride as described for EXAMPLE 30 with the exception that it was not recrystalhzed. Yield 96 mg, 24%: 1H NMR (DMSO) ⁇ 7.8-7.95 (m, 4H), 7.65- 7.75 (m, 2H), 7.35-7.55 (m, 3H), 4.23 (q, 2H), 2.39 (s, 3H), 1.26 (t, 3H); MS-ES (neg) m/z 401.2.
  • EXAMPLE 32 [243H] Ethyl 4-methyl-2- ⁇ [(4-propylphenyl)sulfonyl]amino ⁇ -l,3-thiazole-5-carboxylate This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 4-n-propylbenzenesulfonyl chloride as described for EXAMPLE 30 with the exception that it was not recrystalhzed.
  • This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 2,4,6-trichlorobenzenesulfonyl chloride as described for EXAMPLE 30 with the exception that it was purified by recrystallization only. Yield 249 mg, 58%: 1H NMR (DMSO) ⁇ 7.84 (s, 2H), 4.23 (q, 2H), 2.42 (s, 3H), 1.25 (t, 3H); MS-ES (neg) m/z 429.1.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds with the formula (I) and also to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Description

INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1
TECHNICAL FIELD
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for their preparation, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (llβHSDl).
BACKGROUND ART
1. Glucortieoids- diabetes and hepatic glucose production
It has been known for more than half a century that glucocorticoids have a central role in diabetes, e.g. the removal of the pituitary or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and F.D.W. Leukins (1936) J. Exp. Med. 63: 465- 490; Houssay, B.A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
The role of 1 lβHSDl as an important regulator of local glucocorticoid effect and thus of hepatic glucose production is well substantiated (see e.g. Jamieson et al. (2000) J. Endocrinol. 165: p. 685-692). The hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific llβHSDl inhibitor carbenoxolone (Walker, B.R. et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats. These studies showed that the mRNA levels and activities of two key enzymes in hepatic glucose production were reduced, namely: the rate-limiting enzyme in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6- phosphatase (G6Pase) catalyzing the last common step of gluconeogenesis and glycogenolysis. Finally, the blood glucose level and hepatic glucose production is reduced in mice having the 1 lβHSDl gene knocked-out. Data from this model also confirm that inhibition of 1 lβHSDl will not cause hypoglycemia, as predicted since the basal levels of PEPCK and G6Pase are regulated independently of glucocorticoids (Kotelevtsev, Y. et al., (1997) Proc. Natl. Acad. Sci. USA 94: 14924-14929).
2. Possible reduction of obesity and obesity related cardiovascular risk factors
Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetic, and omental fat appears to be of central importance. Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000). Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e. reduced central obesity (Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: 1210-1213).
Inhibition of 1 lβHSDl in mature adipocytes is expected to attenuate secretion of the plasminogen activator inhibitor 1 (PAI-1) - an independent cardiovascular risk factor (Halleux, CM. et al. (1999) J. Clin. Endocrinol. Metab. 84: 4097-4105). Furthermore, there is a clear correlation between glucocorticoid "activity" and cardiovascular risk factore suggesting that a reduction of the glucocorticoid effects would be beneficial (Walker, B.R. et al. (1998) Hypertension 31: 891-895; Fraser, R. et al. (1999) Hypertension 33: 1364-1368).
Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 1 lβHSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C et al. (1998) Science, 280: 1378-1383).
3. Possible beneficial effect on the pancreas
mhibition of 1 lβHSDl in isolated murine pancreatic β -cells improves the glucose- stimulated sulin secretion (Davani, B. et al. (2000) J. Biol. Chem. 2000 Nov 10; 275(45): 34841-4). Glucocorticoids were previously known to reduce pancreatic insulin release in vivo (Billaudel, B. and B.C.J. Sutter (1979) Horm. Metab. Res. 11: 555-560). Thus, inhibition of llβHSDl is predicted to yield other beneficial effects for diabetes treatment, besides effects on liver and fat.
4. Possible beneficial effects on cognition and dementia
Stress and glucocorticoids influence cognitive function (de Quervain, D.J.-F., B.
Roozendaal, and J.L. McGaugh (1998) Nature 394: 787-790). The enzyme llβHSDl controls the level of glucocorticoid action in the brain and thus contributes to neurotoxiciτy (Rajan, V., C.R.W. Edwards, and J.R. Seckl, J. (1996) Neuroscience 16: 65-70; Seckl, J.R., Front. (2000) Neuroendocrinol. 18: 49-99). Unpublished results indicate significant memory improvement in rats treated with a non-specific 11 βHSDl inhibitor (J. Seckl, personal communication). Based the above and on the known effects of glucocorticoids in the brain, it may also be suggested that inhibiting 1 lβHSDl in the brain may result in reduced anxiety (Tronche, F. et al. (1999) Nature Genetics 23: 99-103). Thus, taken together, the hypothesis is that inhibition of 11 βHSD 1 in the human brain would prevent reactivation of cortisone into cortisol and protect against deleterious glucocorticoid-mediated effects on neuronal survival and other aspects of neuronal function, including cognitive impairment, depression, and increased appetite (previous section). 5. Possible use of immuno-modulation using llβHSDl inhibitors
The general perception is that glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin.
Endocrinol. Metab. 13: 576-581). The balance between the cell-mediated response and humoral responses is modulated by glucocorticoids. A high glucocorticoid activity, such as at a state of stress, is associated with a humoral response. Thus, inhibition of the enzyme llβHSDl has been suggested as a means of sMfting the response towards a cell-based reaction.
In certain disease states, including tuberculosis, lepra and psoriasis the immune reaction is normaly biased towards a humoral response when in fact the appropriate response would be cell based. Temporal inhibition of 1 lβHSDl, local or systemic, might be used to push the immune system into the appropriate response (Mason, D. (1991) Immunology Today 12: 57-60; Rook et al., supra).
An analogous use of llβHSDl -inhibition, in this case temporal, would be to booster the immune response in association with immunization to ensure that a cell based response would be obtained, when desired.
6. Reduction of intraocular pressure
Recent data suggest that the levels of the glucocorticoid target receptors and the . 1 lβHSD enzymes determines the susceptibility to glaucoma (Stokes, J. et al. (2000) Invest. Ophthalmol. 41: 1629-1638). Further, inhibition of llβHSDl was recently presented as a novel approach to lower the intraocular pressure (Walker E. A. et al, poster P3-698 at the Endocrine society meeting June 12-15, 1999, San Diego). Ingestion of carbenoxolone, a non-specific mhibitor of llβHSDl, was shown to reduce the intraocular pressure by 20% in normal subjects. In the eye, expression of 1 lβHSDl is confined to basal cells of the cornea! epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris. In contrast, the distant isσenzyme 1 lβHSD2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage. Thus, 1 lβHSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
7. Reduced osteoporosis
Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess. Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., S.L. Cheng, and G.S. Kim (1999) J. Endocrinol. 162: 371-379). The negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of llβHSDl in the glucocorticoid effect (Bellows, C.G., A. Ciaccia, and J.N.M. Heersche, (1998) Bone 23 : 119-125). Other data suggest a role of 1 lβHSDl in providing sufficiently high levels of active glucocorticoid in osteoclasts, and thus in augmenting bone resorption (Cooper, M.S. et al. (2000) Bone 27: 375-381). Taken together, these different data suggest that inhibition of llβHSDl may have beneficial effects against osteoporosis by more than one mechanism working in parallel.
WO 99/65884 discloses carbon subtituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may e.g. be used against cancer, inflammation and arthritis. US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof. Further, US 5,403,857 discloses benzenesulfonamide derivatives having 5-liρoxygenase inhibitory activity. Additionally, tefrahydrot azolo[5,4-c]pyridines are disclosed in: Analgesic tetiahydrothiazolo[5,4-c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465.
CODEN: FAXXA3; FR 94123 19690704 CAN 72:100685 AN 1970:100685 CAPLUS and 4,5,6,7-TettahyfrotMazolo[5,4-c]pyridines. Neth. Appl. (1967), 39 pp. CODEN: NAXXANNL 6610324 19670124 CAN 68:49593, AN 1968: 49593 CAPLUS.
FR 2384498 discloses thiazolo-benzenesulfonamides which show antibacterial, antifungal and hypoglycaemic properties. WO99/28306 and EP 0 819 681 A2 relate to t azolobenzenesulfonamides which can be used for treating neurodegenerative pathologies, such as Alzheimer's disease. JP 7149745 A2 and JP 7149746 A2 both describe 2-aminothiazole derivatives as esterase inhibitors. Nothing is disclosed about inhibiting llβHSDl. JP 7309757 A2 relates to treating Alzheimer's disease using N- (5-nitio-2-thiazolyl)benzenesulfonamides. JP 3173876 A2 presents preparation of diphenylthiazoles. These compounds are used as anti-inflammatories, analgesics, anti- allergy agents, uric acid accelerators and blood platelet aggregation inhibitors. EP 0 790 057 Al discloses an antibacterial or bactericide comprising a 2-aminothiazole derivative. US 2 362 087 describes the preparation of thiazolobenzenesulfonamides, such as 2-bromobenzenesulfonamido-4-methylthiazole. Notiiing is disclosed about iiihibiting llβHSDl and no therapeutic use of such substances is disclosed.
However, none of the above disclosures discloses the compounds according to the present invention, or their use for the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and depression.
Consequently, there is a need of new compounds that are useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and depression.
DISCLOSURE OF THE INVENTION
The compounds according to the present invention solve the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (11-β-HSDi), and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and depression.
One object of the present invention is a compound of the formula (I)
Figure imgf000008_0001
wherein
T is a monocyclic aryl ring or monocyclic heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, Cι-6-alkyl, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
with the proviso: that when A is methyl and B is hydrogen, then T is not phenyl; that when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4-methylphenyl; that when A is methyl and B is hydrogen, then T is not 4-bromophenyl; that when A is tert-butyl and B is bromo, then T is not 4-chlorophenyl; optionally also when A is methyl and B is hydrogen, then T is not 4-methylρhenyl; optionally also when A is methyl and B is hydrogen, then T is not 4-chlorophenyl; and optionally also when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4- methylphenyl.
A is Ci-6-alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is hydrogen, methyl, ethyl, n-propyl, n-butyl, halogenated Cι-6-alkyl, -6-acyl or . -alkoxycarbonyl; as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
It is preferred that:
T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
with the proviso: that when A is methyl and B is hydrogen, then T is not phenyl; that when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4-methylphenyl; that when A is methyl and B is hydrogen, then T is not 4-bromophenyl; that when A is tert-butyl and B is bromo, then T is not 4-chlorophenyl; optionally also when A is methyl and B is hydrogen, then T is not 4-methylphenyl; optionally also when A is methyl and B is hydrogen, then T is not 4-chlorophenyl; and optionally also when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4- methylphenyl.
A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, 2,2,2-trichloroethyl, acetyl and carbethoxy.
When T is a substituted phenyl group, it is preferred that the phenyl ring is substituted as follows:
a) either T is phenyl, wherein the phenyl is substituted with one or more of 3-chloro- 2-cyanophenoxy, fluoro, phenyl, n-propyl and, in o- or m-position, bromo, chloro, methyl; b) T is phenyl substituted with at least two chloro and optionally one or more methyl; or
c) T is phenyl substituted with one bromo and 2 fluoro.
Specific examples of compounds according to the invention are:
4-chloro-N-(4-methyl- 1 ,3 -tWazol-2-yl)benzenesulfonamide, 3-cMoro-2-methyl-N-(4-methyl-l,3-tMazol-2-yl)benzenesulfonamide, 3-c oro-2-methyl-N-[4-methyl-5-(2,2,2-tricMoroethyl)-l,3-thiazol-2- yl]benzenesulfonamide, N-[4-me l-5-(2,2,2-tricUoroe l)-l,3-t azol-2-yl]-2,4,6-trichloroberizen sulfonamide, 3-cUoro-N-(5-ethyl-4-methyl-l,3-t azol-2-yl)-2-methylbenzenesu--fonami 3 -chloro-2-methyl-N-(4-methyl-5-propyl- 1 ,3 -tMazol-2-yl)benzenesulfonamide,
3 -chloro-N-(4-ethyl- 1 ,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 3-cUoro-N-(4-ethyl-5-methyl-l,3-tlnazol-2-yl)-2-methylbenzenesulfonamide, 3-cMoro-2-methyl-N-(4-propyl-l,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-N-(4-isopropyl- l,3-thiazol-2-yl)-2-methylbenzenesulfonamide, N-(4-butyl-l,3-thiazol-2-yl)-3-chloro-2-memylbenzenesulfonamide,
N-(5-butyl-4-methyl-l,3-tMazol-2-yl)-2,4-dicMoro-6-methylbenzenesulfon- amide, N-(4-tert-butyl-l,3-tltiazol-2-yl)-3-cl_doro-2-methylbenzenesulfonanιide, ethyl 3-(2-{[(2,4-dicMoro-6-me ylphenyl)sulfonyl]amino}-l,3-thiazol-4-yl)-3- methylbutanoate,
2,4-dichloro-6-methyl-N-(4-pentyl- 1 ,3 -t azol-2-yl)benzenesulfonamide, 3-cUoro-2-methyl-N-(4-vmyl-l,3-t azol-2-yl)benzenesulfonamide, N-(5-acetyl-4-methyϊ-l,3-tMazol-2-yl)-4-clιlorobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-3-chloro-2-methylbenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-t azol-2-yl)[l, -biρhenyl]-4-s fonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-(3-chloro-2-cyanophenoxy)benzene- sulfonamide, N-(5-acetyl-4-meu^yl-l,3-tMazol-2-yl)-4-propylberιzenesulfonamide, N-(5-acetyl-4-methyl-l,3-t--nazol-2-yl)-2,4,6-tricMoroberιzenesulfo N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,4-dicMoro-6-methylbenzenesulfon- amide, N-(5-ace1yl-4-methyl-l,3-tMazol-2-yl)-2,4,5-1ricWoroberιzenesulfonantid N-(5-aceryl-4-methyl-l,3-tMazol-2-yl)-4-bromo-5-cMoro-2-tMenylsulfonamide, N-(5-ace1yl-4-methyl-l,3-thiazol-2-yl)-4-bromo-2,5-difluoro-2-benzenesulfon- amide,
N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-2,6-(hcUorobenzenesulfonamide, N-(5-carbemoxy-4-methyl-l,3-thiazol-2-yl)-3-cMoro-2-methylbenzene- sulfonamide, N-(5-carbe1hoxy-4-memyl-l,3-tMazol-2-yl)[l, -biphenyl]-4-s fonamide, N-(5-carbethoxy-4-methyl-l,3-tMazol-2-yl)-4-propylbenzenesulfonamide,
N-(5-carbethoxy-4-methyl-l,3-tWazol-2-yl)-2,4-dichloro-6-methylbenzene- sulfonamide, N-(5-carbethoxy-4-memyl-l,3-tmazol-2-yl)-2,4,6-tricUorobenzenesulfonanti
Another object of the present invention is a compound as described above for medical use.
Another object of the present invention is a process for the preparation of a compound as described above comprising at least one of the following steps: a) sulfonamide coupling by reacting a 2-aminothiazole with a sulfonylchloride in the presence of a base, b) sulfonamide coupling by reacting a 2-aminothiazole derivative with a sulfonylchloride in the presence of a base, c) saponification by treatment of a carboxylic acid ester with aqueous hydroxide, d) amide coupling by reacting a carboxylic acid with an amine in the presence of
EDCI, e) formation of a thiazole ring by reacting an optionally substituted thiourea with an α-haloketone, f) formation of a thiazole ring by reacting a thiourea with a ketone, g) reduction of an ester with lithium aluminium hydride, h) conversion of an alcohol to a bromide with triphenylphosphine and carbon tetrabromide, i) elimination of a bromide with a base to an alkene.
Another object of the present invention is a method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and mflammatory disorders, said method comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound of the formula (I)
Figure imgf000012_0001
wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]„, wherein n is an integer 0-5, and R is hydrogen,
Figure imgf000012_0002
halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
A is Cι-6-alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is hydrogen, halogen, Cι-6-alkyl, halogenated Cι-6-alkyl, Ci-e-acyl or Cι-6- alkoxycarbonyl; as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
These compounds may also be used in the manufacture of a medicament for the prevention, management or treatment of diabetes, syndrome X, obesity, glaucoma, hyperHpidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.
It is preferred that:
T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3 -(ethyl 3-methylbutanoate);
B is selected from hydrogen, bromo, methyl, ethyl, n-propyl, n-butyl, 2,2,2- trichloroethyl, acetyl and carbethoxy.
Specific examples of compounds according to the invention are:
4-chloro-N-(4-methyl- l,3-tMazol-2-yl)benzenesulfonamide,
N-(4-methyl-l,3-tMazol-2-yl)benzenesulfonamide,
3-cMoro-2-methyl-N-(4-methyl-l,3-thiazol-2-yl)benzenesulfonamide, 4-cHoro-N-[4-methyl-5-(2,2,2-trichloroe.hyl)-l,3-thiazol-2- yljbenzenesulfonamide,
3-cUoro-2-methyl-N-[4-memyl-5-(2,2,2-tric oroethyl)-l,3-thiazol-2- yljben-zenesulfonamide,
N-[4-methyl-5-(2,2,2-tricMoroethyl)-l,3-t^ sulfonamide,
3-cHoro-N-(5-emyl-4-methyl-l,3-tM 3-cWoro-2-methyl-N-(4-methyl-5-propyl-l,3-u4iazol-2-yl)benzenesulfonamide, 3-cWoro-N-(4-ethyl-l,3-tMazol-2-yl)-2-memylbenzenesulfonamide, 3-cMoro-N-(4-ethyl-5-methyl-l,3-tMazol-2-yl)-2-methylberιzenesu-lfo 3-cWoro-2-methyl-N-(4-propyl-l,3-tltiazol-2-yl)benzenesulfonanιide, 3-chloro-N-(4-isopropyl- l,3-thiazol-2-yl)-2-methylbenzenesulfonamide,
N-(4-butyl- 1 ,3 -thiazol-2-yl)-3-chloro-2-methylbenzenes fonamide, N-(5-butyl-4-methyl-l,3-u^azol-2-yl)-2,4-dcWoro-6-methylbenzenesulfon- amide, N-(4-tert-butyl-l,3-tmazol-2^yl)-3-chloro-2-methylbenzenesulfonamide, ethyl 3-(2-{[(2,4-dicUoro-6-methylphenyl)sulfonyl]anmιo}-l,3-thiazol-4-yl)-3- methylbutanoate, 2,4-ά^cUoro-6-memyl-N-(4-pentyl-l,3-tMazol-2-yl)benzenesulfonaιnide, 3 -chloro-2-methyl-N-(4- vinyl- 1 , 3 -thiazol-2-yl)benzenes fonamide, N-(5-acetyl-4-memyl-l,3-tMazol-2-yl)-4-cMorobenzenesulfonamide, N-(5-acetyl-4-methyl- l,3-thiazol-2-yl)-3 -chloro-2-methylbenzenesulfonamide,
N-(5-acetyl-4-methyl- 1 ,3-thiazol-2-yl)[ 1 , 1 '-biphenyl]-4-sulfonamide, N-(5-acetyl-4-methyl- 1 ,3 -thiazol-2-yl)-4-(3 -chloro-2-cyanophenoxy)benzene- sulfonamide, N-(5-acetyl-4-memyl-l,3-tMazol-2-yl)-4-propylbenzenesulfonamide, N-(5-acetyl-4-memyl-l,3-iMazol-2-yl)-2,4,6-tricUorobenzenes fonan_ύde,
N-(5-acetyl-4-memyl-l,3-tMazol-2-yl)-2,4-d chloro-6-methylbenzenesulfon- amide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-2,4,5-tricWoroberizenesιdfonan_tide, N-(5-acetyl-4-memyl-l,3-t azol-2-yl)-4-bromo-5-c oro-2-tMenyls fonamide, N-(5-acetyl-4-memyl-l,3-t azol-2-yl)-4-bromo-2y5-difluoro-2-benzenesulfon- amide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,6-o c^ N-(5-carbethoxy-4-methyl-l,3-thiazol-2-yl)-3-chloro-2-methylbenzene- sulfonamide, N-(5-carbethoxy^4-methyl- l,3-thiazol-2-yl)[ 1, 1 '-biρhenyl]-4-sulfonamide,
N-(5-carbethoxy-4-me yl-l,3-tMazol-2-yl)-4-propylbenzenesulfonamide, N-(5-carbethoxy-4-memyl-l,3-t azol-2-yl)-2,4-dicUoro-6-methylbenzene- sulfonamide,
N-(5-carbethoxy-4-methyl-l,3-tWazol-2-yl)-2,4,6-tricUoroberi2;enesulfo N-[5-bromo-4-(tert-bu1yl)-l,3-l azol-2-yl]-4-cmorobenzenesulfonamide.
Another object of the present invention is a pharmaceutical composition comprising at least one compound of the formula (I) as defined above, and a pharmaceutically acceptable carrier.
The compounds according to the present invention may be used in several indications which involve 11-β-hydroxysteroid dehydrogenase type 1 enzyme. Thus the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis E 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical Endocrinology and Metabolism, 81, 3441-3447) and may also be used disorders in the immune system (see Franchimont et al, "Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes", The journal of Immunology 2000, Feb 15, vol 164 (4), pages 1768-74) and also in the above listed indications.
The various terms used, separately and in combinations, in the above definition of the compounds having the formula (I) will be explained.
The term "aryl" in the present description is intended to include aromatic rings (monocychc or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph; a monocyclic ring) and naphthyl (a bicyclic ring), which optionally may be substituted by Ci-e-alkyl. Examples of substituted aryl groups are benzyl and 2-methylρhenyl.
The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium. Examples.of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cmnoline, quinazoline, indple, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2,1,3-benzothiazole, 2,1,3- benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4- tehahydroqumoline, 3,4-ό^ydro-2-7-l,4-ber-zoxazme, 1,5-naphthyridine, 1,8- naphthyridine, acridine, fenazine and xanthene. Examples of monocyclic heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiaz le, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, and tetrazole.
Cχ_6~alkyl in the compound of formula (I) according to the present apphcation, which may be straight or branched, is preferably Ci-4-alkyl. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, hexyl, and isohexyl.
C i-.6-alkoxy, in the compound of formula (I) according to the present application may be straight or branched, is preferably Cι_4-alkoxy. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy.
C χ_6-acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably Cι_4-acyl. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3- butenoyl), hexenoyl (e.g. 5-hexenoyl). The term "halogen" in the present description is intended to include fluorine, chlorine, bromine and iodine.
The term "prodrug forms" in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-15).
"Pharmaceutically acceptable" means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
"Pharmaceutically acceptable salts" mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, ftm aric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like.
Pharmaceutical compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a human patient for therapeutic purposes, unless that purpose is to induce an immune response. The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
The active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient. Adjuvants may also be present in the composition.
Pharmaceutically acceptable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes.
Liquid compositions can also contain liquid phases in addition to and to t e exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
The pharmaceutical composition according to one of the preferred embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
The preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously. Other routes which are known for the skilled person in the art are thinkable.
The orally administrable compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrohdone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant e.g. magnesium stearate, talc, polyethylene glycol or silica; disintegrants e.g. potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g. lecitiiin, sorbitan monooleate or acacia, non-aqueous vehicles (which may include edible oils), e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
A pharmaceutical composition according to the present invention, may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition. A weight percent is a ratio by weight of total composition. Thus, for example, 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition. A suitable daily oral dose for a mammal, preferably a human being, may vary widely depending on the condition of the patient. However a dose . of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
The compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier.
The compounds of the present invention in labelled form, e.g. isotopically labelled, may be used as a diagnostic agent.
The compounds of the formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in-vitro was studied using the following reagents and methods.
All publications mentioned herein are hereby incorporated by reference. By the expression "comprising" we understand including but not limited to. Thus, other non- mentioned substances, additives or carriers may be present.
The invention will now be described in reference to the following Figures and Examples. These Figures and Examples are not to be regarded as limiting the scope of the present invention, but shall only serve in an illustrative manner. EXPERIMENTAL METHODS
Scintillation Proximity Assay
[1, 2(n) - H]-cortisone was purchased from Amersham Pharmacia Biotech. Anti- cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech. NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma. The human 11-β-hydroxysteroid dehydrogenase type-1 enzyme (11-β-HSD was expressed in Pichiapastoris. 18-β-glycyrrhetinic acid (GA) was obtained from Sigma. The serial dilutions of the compounds were performed on a Tecan Genesis RSP 150. Compounds to be tested were dissolved in DMSO (1 mM) and diluted in 50 mM Tris- HC1, pH 7.2 containing 1 mM EDTA.
The multiplication of plates was done on a WallacQuadra. The amount of the product [3H]-cortisol, bound to the beads was determined in a Packard, Top Count microplate liquid scintillation counter.
The 11-β-HSDi enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total weil volume of 220 μL and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 μM), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 μM). Reactions were initiated by the addition of human 11-β-HSDt, either as Pichiapastoris cell homogenate or microsomes prepared from Pichiapastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL). Following mixing, the plates were shaken for 30 to 45 minutes at room temperature. The reactions were terminated with 10 μL 1 mM GA stop solution. Monoclonal mouse antibody was then added (10 μL of 4 μM) followed by 100 μL of SPA beads (suspended according to the manufacturers instructions). Appropriate controls were set up by omitting the 11-β- HSDi to obtain the non-specific binding (NSB) value.
The plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting. The amount of [3H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter.
The calculation of the Kj values for the inhibitors was performed by use of Activity Base. The K; value is calculated from IC50 and the Km value is calculated using the Cheng Prushoff equation (with reversible inhibition that follows the Michaelis-Menten equation): Kj = IC50(l+[S]/Km) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108]. The IC50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance. The Ki values of the compounds of the present invention for the 11- β-HSDl enzyme he typically between about 10 nM and about 10 μM. Illustrative of the invention, the following Ki values have been determined in the human 11 -β-HSDl enzyme assay (see Table 1):
Table 1: Ki values determined in the human 11-β-HSDl enzyme assay.
Figure imgf000022_0001
COMPOUND PREPARATION
General: For preparative straight phase HPLC purification a Phenomenex column (250 x 21.1 mm, 10 μm) was used on a Gilson system eluting with ethanol in chloroform (gradient from 0 - 10% in 10 min) with a flow of 20 mL/min. Column chromatography was performed on silica using Silica gel 60 (230-400 mesh), Merck. Melting points were determined on a Gallenkamp apparatus. Elemental analyses were recorded using a Vario EL instrument. HPLC analyses were performed using a Hypersil Elite column (150 x 4.6 mm, 3μ) with a flow of 3 mL / min on a Waters 600E system with monitoring at 254 nm. Reverse phase preparative HPLC was carried out on a 100 x 21.2 mm, 5μ Hypersil Elite column eluting with a gradient of 5% ACN in 95% water to 95% ACN in 5% water (0.2% TFA buffer) over 10 mins at a flow rate of 20 mL / min with the UV detector set at 254 nm. Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Electrospray MS spectra were obtained on a Micromass platform LCMS spectrometer. Crude, worked up compounds were purified.by flash column chromatography using pre packed silica SPE columns (10 g silica) on an Isco Foxy 200 Combiflash system, and a gradient of 16.67% ethyl acetate in hexane increasing incrementally to 100% ethyl acetate.
List of Abbreviations
DCM = dichloromethane
DIEA = N,N-ά isopropylethylamine DMAP = 4-dimethylammopyridine
DME = ethyleneglycol dimethyl ether
DMF = dimethylformamide
DMSO = dimethyl sulfoxide
EDCI = l-(3-ώmethylan_ιmoρroρyl)-3-ethylc^bodhmide hydrochloride EDTA = ethylene&aminetetraacetic acid
HCOOH = formic acid
HOAT = l-hydroxy-7-azabenzotriazole
HOBT = 1-hydroxybenzotriazole hydrate
MTBE = tert-butyl methyl ether TEA = triethylamine
THF = tetiahydrofuran SULFONAMIDE COUPLINGS: .
METHOD A: 1 Eq of the 2-aminothiazole was dissolved in pyridine (0.5 M solution). The sulfonyl chloride (1.2 eq) was added and the reaction mixture was stirred at ambient temperature under nitrogen atmosphere for 15 h. The reaction mixture was poured into aqueous HC1 (1 M). If the product precipitated it was collected on a filter and washed with aqueous HC1 (1 M) and recrystallised from ethanol. In case an oil was obtained, the crude was extracted with DCM and worked up and purified using standard procedures.
METHOD B:
A solution of the 2-aminothiazole derivative (1 eq), triethylamine (2 eq) and DMAP (1 eq) in DMF (1 M) and DCM (0.225 M) was dispensed into a reaction vial, The sulfonyl chloride (1.2 eq) was dissolved in DCM (0.33 M) and added. The reaction mixtures were kept at room temperature over night. The mixture was then added to petroleum ether (10 times reaction volume). After some hours in refrigerator the supernatants were decanted and (a portion of) the residual materials were dissolved in DMSO-methanol-acetic acid (300 μL + 500 μL + 50 μL) and purified by preparative LCMS (acetonitrile-water gradients). The purest fractions were collected and lyophilized. Alternatively, the crude was isolated using extractive work-up and purified using standard procedures.
SAPONIFICATIONS:
r
METHOD C:
1 Eq of the ester was suspended in 95% ethanol (0.1 M) and treated with KOH (aqueous, 6 eq). Water was added until a clear solution was achieved. The reaction mixture was stirred for 2-3 h at ambient temperature. The solvent was removed under reduced pressure and the crude was redissolved in water. Addition of cone. HC1 until pH 2 gave a precipitate which was collected on a filter and washed with cold water and dried.
AMIDE COUPLINGS:
METHOD E:
The carboxylic acid was suspended in DCM (0.05M) followed by the addition of EDCI (1.1 eq), triethylamine (3 eq), DMAP (0.5 eq) and the amine of choice (1.2 eq). DMF was added when the starting materials did not dissolve properly. The reaction mixture was stirred at ambient temperature over night. The organic phase was washed with aqueous HC1 (1 M), dried over sodium sulfate, filtered and evaporated in vacuo. The crude product amide was purified by flash column chromatography on sihca gel, eluting with methanol (1— 3— »6%) in DCM or ethyl acetate.
FORMATION OF THIAZOLE RING:
METHOD H:
To a solution or suspension of an optionally substituted thiourea in ethanol (0.5 M), 1 equivalent of α-haloketone was added at room temperature. The reaction mixture was stirred in a sealed tube at 95 °C for 4 h, cooled, concentrated, redissolved in ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate, dried over sodium sulfate and chromatographed on silica gel using petroleum-ether and ethyl acetate as eluents.
METHOD I:
To a 0.5 M solution of ketone (1 eq) and thiourea (2 eq) in ethanol at 60 °C, 1 eq of iodine was added in one portion. The reaction tube was sealed and the reaction mixture was stirred at 100 °C for 16 hours. After evaporation of the solvent the residue was taken up in DCM, washed with saturated aqueous sodium hydrogen carbonate, dried with magnesium sulfate. Products were purified by chromatography on silica gel using a gradient of petroleum-ether / ethyl acetate from 8: 1 to 2: 1 for elution. KNOWN EXAMPLES
The compounds of the following Examples 2, 4 and 35 are commercially available and could e g be purchased from Maybridge.
2 [216A] N-(4-Methyl-l,3-tr azol-2-yl)benzenesulfonamide 4 [218A] 4-memyl-N-[4-methyl-5-(2,2,2-tricmoroethyl)-l,3-thiazol-2- yl]benzenesulfonamide 35 [341A] N-[5-bromo-4-(tert-butyl)-l,3-tlήazol-2-yl]-4-cWorobenzenesulfonamide
NOVEL EXAMPLES
The following specific compounds were synthesized. The commercially available compounds thus only form embodiments, as indicated earher in the description, as pharmaceutical compositions and use of said compounds as set out in the appended set of claims.
EXAMPLE 1 [215A] 4-Chloro-N-(4-methyl-l,3-thiazol-2-yl)benzenesuIfonamide
The title compound was prepared according to METHOD A, giving 143 mg (41%) after recrystallization from DCM: MS (Ionspray, [M+H]+) m/z 288; Anal. Calcd. (found) for C10H9ClN2O2S2: C 41.6 (41.5) % H 3.1 (2.7) % N 9.7 (9.3) %.
EXAMPLE 3 [217A]
3-Chloro-2-methyI-N-(4-methyl-l,3-thiazol-2-yl)benzenesulfonamide
The title compound was prepared from 2-ammo-4-methylthiazole (285 mg) and 3- chloro-2-methylbenzenesulfonyl chloride (619 mg) according to METHOD A. This afforded 167 mg (22%) of a yellow solid after purification: 1H NMR (DMSO-ck) δ 2.1 (s, 3H), 2.6 (s, 3H), 6.35 (s, IH), 7.35 (t, IH), 7.65 (d, IH), 7.85 (d, IH), 12.7 (br s, IH). EXAMPLE 5 [219A]
3-Chloro-2-methyl-N-[4-methyl-5-(2,2,2-trichloroethyI)-l,3-thiazol-2- yljbenzenesulfonamide The title compound was prepared similar to EXAMPLE 6 according to METHOD A from 4-methyl-5-(2,2,2-tricUoroemyl)-l,3-tMazol-2-ylamine (123 mg, 0.5 mmol) and 3-chloro-2-methylbenzenesulfonyl chloride (112.5 mg, 0.5 mmol). The solution was allowed to stand at r.t. overnight. Water (5 mL) was added and the resulted solution was made acidic with cone. HC1. The precipitate was filtered, washed with water and dried. Flash column chromatography of the precipitate on silica gel, eluted with a mixed solvents of ethyl ether and hexane (2:1) gave the title compound as a solid (165 mg, 76% yield). The product can be recrystallized from ethyl acetate and hexane: MS m/e: 439, 437, 435, 433.
EXAMPLE 6 [220A]
2,4,6-trichloro-N-[4-methyl-5-(2,2,2-trichloroethyl)-l,3-thiazoI-2- yl]benzenesuIfonamide
The title compound was prepared according to METHOD A from 4-methyl-5-(2,2,2- tricMoroe yl)-l,3-tMazol-2-ylamine (123 mg, 0.5 mmol, prepared according to Dodinov, A.A et al (1993) Chem. Heterocycl. Comp (Eng. Transl.) 29(8): 955-958) and 2,4,6-trichlorobenzenesulfonyl chloride (140 mg, 0.5 mmol). The solution was allowed to stand at room temperature overnight. The solution was directly loaded on a silica gel column for flash column chromatography, eluted with a mixed solvent of ethyl acetate and hexane (up to 40 % v/v) to give a solid product. Crystallization of the product from ethyl acetate and hexane gave the title compound as a white solid (112 mg, 46 % yield): mp 228-229 °C;MS m/e 487, 489, 491, 493; Anal. Calcd. (found) for C12H8Cl6N2θ2S2: C 29.5 (29.7) % H 1.7 (2.1) % N 5.7 (5.8) %. EXAMPLE 7 [221A] 3-Chloro-N-(5-ethyI-4-methyl-l,3-thiazoI-2-yl)-2-methylbenzenesuIfonamide
The title compound was prepared from 5-ethyl-4-methyl-l,3-tMazol-2-ylamine (METHOD I) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellow solid, 42mg (25% yield): HRMS Calcd (found) for C13H15C1N202S2 m/z 330.0263 (330.0250).
EXAMPLE 8 [222A] 3-ChIoro-2-methyl-N-(4-methyl-5-propyl-l,3-thiazol-2-yl)benzenesulfonamide The title compound was prepared from 4-methyl-5-propyl- l,3-thiazol-2-ylamine
(METHOD I) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellow solid, 1 lOmg (46% yield): HRMS Calcd (found) for Cι4H17ClN202S2 m/z 344.0420 (344.0403).
EXAMPLE 9 [224A]
3-Chloro-N-(4-ethyI-l,3-thiazol-2-yl)-2-methylbenzenesulfonamide
The title compound was prepared from 4-e1hyl-l,3-tMazol-2-ylamine (METHOD H) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellowish solid, 53 mg (17% yield): HRMS Calcd (found) for Cι2H13ClN202S2 m/z 316.0107 (316.0120).
EXAMPLE 10 [225A] 3-Chloro-N-(4-ethyl-5-methyl-l,3-thiazol-2-yI)-2-methylbenzenesulfonamide
The title compound was prepared from 4-ethyl-5-methyl-l,3-thiazol-2-ylamine (METHOD I) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellowish foam, 40 mg (12% yield): HRMS Calcd (found) for Cι3Hι5ClN202S2 m/z 330.0263 (330.0271). EXAMPLE 11 [226A] 3-Chloro-2-methyl-N-(4-propyl-l,3-thiazoI-2-yl)benzenesulfonamide
The title compound was prepared from 4-propyl-l,3-tltiazol-2-ylamine (METHOD I) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellow solid, 90 mg (39% yield): mp 169 °C; HRMS Calcd (found) for Ci3H15ClN202S2 m/z 330.0263 (330.0251).
EXAMPLE 12 [227A] 3-Chloro-N-(4-isopropyl-l,3-thiazol-2-yl)-2-methyIbenzenesuIfonamide The title compound was prepared from 4-isopropyl-l,3-thiazol-2-ylamine (METHOD I) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, white foam, 80 mg (48% yield): HRMS Calcd (found) for Cι3Hι5ClN202S2 m z 330.0263 (330.0257).
EXAMPLE 13 [228A]
N-(4-Butyl-l,3-thiazol-2-yl)-3-chloro-2-methylbenzenesuIfonamide
The title compound was prepared from 4-butyl-l,3-t azol-2-ylamine (METHOD H) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, yellow solid, 52 mg (22% yield): HRMS Calcd (found) for Cι4Hi7ClN202S2 m z 344.0420 (334.0414).
EXAMPLE 14 [229A] N-(5-butyI-4-methyl-l,3-thiazoI-2-yl)-2,4-dichloro-6-methyIbenzenesulfonamide
The title compound was prepared from 5-butyl-4-methyl-l,3-tMazol-2-ylamine (METHOD I) and 2,4-dichloro-6-methylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a yellow solid (41 mg) with purity >90%. MS (pos) m/z 393.2, 395.2. EXAMPLE 15 [230A] N-(4-Tert-butyl-l,3-thiazoI-2-yl)-3-ehloro-2-methylbenzenesulfonamide
The title compound was prepared from 4-tert-butyl-l,3-tbiazol-2-ylamine (METHOD H) and 3-chloro-2-methylbenzenesulfonyl chloride according to METHOD A, white foam, 273 mg (40% yield), mp 178 °C; HRMS Calcd (found) for Cι4Hι7ClN202S2 m/z 344.0420 (344.0408).
EXAMPLE 16 [231A]
Ethyl 3-(2-{[(2,4-dichloro-6-methylphenyl)suIfonyl]amino}-l,3-thiazol-4-yl)-3- methylbutanoate
The title compound was prepared from ethyl 3-(2-amino-l,3-thiazol-4-yl)-3- methylbutanoate (METHOD I) and 2,4-dichloro-6-methylbenzenesulfonyl chloride as described in the synthetic method to give a white solid (55.0 mg) with purity >90%. MS (pos) m/z 451.2, 453.2.
EXAMPLE 17 [232A]
2,4-Dichloro-6-methyl-N-(4-pentyI-l,3-thiazol-2-yl)benzenesulfonamide The title compound was prepared from 4-pentyl-l,3-thiazol-2-ylamine (METHOD I) and 2,4-ώchloro-6-methylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a white solid (28.6 mg) with purity >90%. MS (pos) m/z 393.1, 395.L
EXAMPLE 18 [233A] 3-Chloro-2-methyl-N-(4-vinyl-l,3-thiazol-2-yI)benzenesulfonamide The title compound was prepared in the following steps 1-4:
Step 1
Ethyl 2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl]amino} - 1 ,3 -thiazol-4-yl)acetate was prepared according to METHOD A at 30°C, using a Quest 210 apparatus. This procedure gave 2.05 g (34%) of an off-white solid. Step 2
To a solution of the product from Step 1 (5.00 g, 13.34 mmol) in tetrahydrofuran (200 mL) was added litium aluminum hydride (1.06 g, 28.02 mmol) in small portions. The temperature was kept below 0°C during the addition, and the mixture was stirred for 45 min. at 0°C, treated with water (1 mL), cone. HC1 (1 mL) and water (1 mL). Sodium sulfate was added and the solid was filtered off. The solvent was evaporated and the crude product was purified by flash column chromatography on sihca gel eluting with 20% acetone in dichloromethane to yield the product (2.41 g, 7.24 mmol, 54 %).
10
Step 3
An ice-cold mixture of the product from Step 2 (2.03 g, 6.10 mmol), triphenylphosphine (4.80 g, 18.31 mmol) and carbon tetrabromide (6.07 g, 18.31 mmol) in DMF (30 mL) was stirred for 1.5 h, and was then poured into water. The
15 mixture was extracted with dichloromethane, dried (sodium sulfate) and the solvent was evaporated. The crude material was twice purified by flash chromatography on silica gel gradient eluting with 0-4 % acetone in dichloromethane giving N-[4-(2- bromoethyl)-l,3-tMazol-2-yl]-3-cMoro-2-methylbenzenesulfonamide as a solid (990 mg, 41 %).
20.
Step 4
Sodium hydride (95 % dry, 32 mg, 1.27 mmol) was added to a stirred solution of the product from Step 3 (240 mg, 0.61 mmol) and 3-hydroxypyridine (63 mg, 0.67 mmol) in tefrahydrofuran (10 mL) at 0 °C. After 2 h at reflux temperature the reaction was
25 neutralized by adding 2 M HC1 and the product mixture was extracted with dichloromethane. The organic phase was dried (Na2S04) and the solvent was evaporated. The crude material was purified by flash chromatography on sihca gel gradient eluting with 2-5 % acetone in dichloromethane giving the title compound as a solid (33 mg, 17%). MS (Ionspray, [M+H]+) m/z 314; Anal. Calcd. (found) for
30 Cι2HπClN2θ2S2: C 45.8 (45.0) % H 3.5 (3.9) % N 8.9 (9.1) %.' EXAMPLE 19 [237A] N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-chlorobenzenesulfonamide
The title compound was prepared from 5-acetyl-2-ammo-4-methylthiazole and 4- chlorobenzenesulfonyl chloride as described in the synthetic METHOD B to give a white solid (12.2 mg) with purity >90%. LCMS (pos) m/z 331.2.
EXAMPLE 20 [238A] N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-3-chloro-2-methyIbenzenesulfonamide
The title compound was prepared from 5-acetyl-2-an_-ino-4-methylthiazole and 3- chloro-2-methylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a white solid (10.8 mg) with purity >90%. LCMS (pos) m/z 345.0.
EXAMPLE 21 [239A] N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)[l,l'-biphenyl]-4-sulfonamide The title compound was prepared from 5-acetyl-2-ammo-4-methylthiazole and 4- biphenylsulfonyl chloride as described in the synthetic METHOD B to give a white solid (5.5 mg) with purity >90%. LCMS (pos) m/z 372.8.
EXAMPLE 22 [240A] N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-(3-chloro-2- cyanophenoxy)benzenesulfonamide
The title compound was prepared from 5-acetyl-2-an_iino-4-methylthiazole and 4-(3- chloro-2-cyanophenoxy)benzenesulfonyl chloride as described in the synthetic METHOD B to give a white solid (9.9 mg) with purity >90%. LCMS (pos) m/z 448.0; LCMS (neg) m/z 446.0.
EXAMPLE 23 [241A] N-(5-acetyI-4-methyl-l,3-thiazol-2-yl)-4-propylbenzenesulfonamide
The title compound was prepared from 5-acetyl-2-aπιmo-4-methylthiazole and 4-n- propylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a white sohd (11.6 mg) with purity >90%: MS (pos) m/z 339.2; HRMS m/z 338.0748 (calc. of monoisotopic mass for C15H18N2θ3S2 gives 338.0759).
EXAMPLE 24 [242A] N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,4,6-trichlorobenzenesulfonamide
The title compound was prepared from 5-acetyl-2-ammo-4-methylthiazole and 2,4,6- trichlorobenzenesulfonyl chloride as described in the synthetic METHOD B to give a white-yellow solid (15.5 mg) with purity >90%. MS (pos) m/z 399.1, 401.1, 403.1.
EXAMPLE 25 [243A]
N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,4-dichloro-6-methylbenzenesulfonamide
The title compound was prepared from 5-acetyl-2-amino-4-methylthiazole and 2,4- dichloro-6-methylbenzenesulfonyl chloride as described in the synthetic METHOD B to give a white-yellow solid (28.4 mg) with purity >90%. MS (pos) m/z 379.1, 381.1.
EXAMPLE 26 [243BJ
N-(5-Acetyl-4-methyl-l,3-thiazol-2-yl)-2,4,5-trichlorobenzenesuIfonamide The title compound was prepared from 5-acetyl-2-amino-4-methylthiazole (42 mg) and 2,4,5-trichlorobenzenesulfonyl chloride (76 mg) as described in the synthetic METHOD B to give a white sohd (23.7 mg) with purity >90%: MS (pos) m/z 399.2, 401.2; HRMS m/z 397.9103 (calc. of monoisotopic mass for Ci2H9Cl3N2θ3S2 gives 397.9120).
EXAMPLE 27 [243C] N-(5-Acetyl-4-methyl-l,3-thiazol-2-yl)-4-bromo-5-chloro-2-thiophenesulfonamide The title compound was prepared from 5-acetyl-2-aπιmo-4-methylthiazole (42 mg) and 4-bromo-5-chlorothiophene-2-sulfonyl chloride (80 mg) as described in the synthetic METHOD B to give a white solid (11.7 mg) with purity >90%: MS (pos) m z 415.3, 417.3. EXAMPLE 28 [243D] N-(5-Acetyl-4-methyI-l,3-thiazol-2-yI)-4-bromo-2,5-difluorobenzenesulfonamide
The title compound was prepared from 5-acetyl-2-aπι o-4-methylthiazole (42 mg) and 4-bromo-2,5-d fluorobenzenesulfonyl chloride (79 mg) as described in the synthetic METHOD B to give a white solid (21.0 mg) with purity >90%: MS (pos) m/z 411.2, 413.2.
EXAMPLE 29 [243E] N-(5-Acetyl-4-methyI-l,3-thiazol-2-yl)-2,6-dichlorobenzenesulfonamide The title compound was prepared from 5-acetyl-2-amino-4-methylthiazole (42 mg) and 2,6-dichlorobenzenesulfonyl chloride (66 mg) as described in the synthetic METHOD B to give a white solid (21.4 mg) with purity >90%: MS (pos) m/z 365.3, 367.3.
EXAMPLE 30 [243F]
Ethyl 2-{[(3-chloro-2-methylphenyl)sulfonyI]amino}-4-methyl-l,3-thiazoIe-5- carboxylate
Ethyl 2-an---no-4-methylthiazole-5-carboxylate (186 mg, 1.0 mmol) and DMAP (122 mg, 1.0 mmol) was mixed with DCM (4 mL) and Et3N (0.28 mL, 2.0 mmol). The mixture was cooled in ice. 3-Chloro-2-methylbenzenesulfonyl chloride (236 mg, 1.05 mmol) was added in two portions. After lA h the mixture was stirred at room temperature and left overnight. More DCM was added and the solution was washed with aqueous HC1 (0.2 M), water and aqueous sodium bicarbonate (0.1 M). A precipitate was separated from the solution. The solution was passed through a silica gel column, eluting with 2% methanol / DCM to give a product (73 mg after recryst. from methanol). The precipitate was combined with the 73 mg and recrystallized from methanol. Yield 266 mg, 71%: 1H NMR (DMSO) δ 13.3 (bs, IH), 7.91 (d, IH), 7.70 (d, IH), 7.41 (s, IH), 4.20 (q, 2H), 2.62 (s, 3H), 2.39 (s, 3H), 1.24 (q, 3H); MS ES (neg) m/z 373.1. EXAMPLE 31 [243G]
Ethyl 2-[([l,l,-biphenyl]-4-ylsulfonyl)amino]-4-methyI-l,3-thiazole-5-carboxylate
This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 4-biphenylsulfoiryl chloride as described for EXAMPLE 30 with the exception that it was not recrystalhzed. Yield 96 mg, 24%: 1H NMR (DMSO) δ 7.8-7.95 (m, 4H), 7.65- 7.75 (m, 2H), 7.35-7.55 (m, 3H), 4.23 (q, 2H), 2.39 (s, 3H), 1.26 (t, 3H); MS-ES (neg) m/z 401.2.
EXAMPLE 32 [243H] Ethyl 4-methyl-2-{[(4-propylphenyl)sulfonyl]amino}-l,3-thiazole-5-carboxylate This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 4-n-propylbenzenesulfonyl chloride as described for EXAMPLE 30 with the exception that it was not recrystalhzed. Yield 315 mg, 85%: 1H NMR (DMSO) δ 7.70 (d, 2H), 7.37 (d, 2H), 4.21 (q, 2H), 2.60 (t, 2H), 2.38 (s, 3H), 1.58 (m, 2H), 1.25 (t, 3H), 0.87 (t, 3H); MS-ES (neg) m/z 367.2.
EXAMPLE 33 [2431]
Ethyl 2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-4-methyl-l,3-thiazole-5- carboxylate This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 2,4-dichloro-6-methylbenzenesulfonyl chloride as described for EXAMPLE 30. Yield 254 mg, 62%: 1H NMR (DMSO) δ 7.64 (d, IH), 7.53 (d, IH), 4.22 (q, 2H), 2.67 (s, 3H), 2.41 (s, 3H), 1.25 (t, 3H); MS-ES (neg) m/z 407.1.
EXAMPLE 34 [243J]
Ethyl 4-methyl-2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-l,3-thiazoIe-5- carboxylate
This compound was prepared from ethyl 2-amino-4-methylthiazole-5-carboxylate and 2,4,6-trichlorobenzenesulfonyl chloride as described for EXAMPLE 30 with the exception that it was purified by recrystallization only. Yield 249 mg, 58%: 1H NMR (DMSO) δ 7.84 (s, 2H), 4.23 (q, 2H), 2.42 (s, 3H), 1.25 (t, 3H); MS-ES (neg) m/z 429.1.
Various embodiments of the present invention have been described above but a person skilled in the art realizes further minor alterations which would fall into the scope of the present invention. The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.

Claims

Claims
1. A compound of the formula (I)
Figure imgf000037_0001
wherein
T is a monocyclic aryl ring or monocychc heteroaryl ring, optionally independently substituted by [R]„, wherein n is an integer 0-5, and R is hydrogen, Cι.6-alkyl, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
with the proviso: that when A is methyl and B is hydrogen, then T is not phenyl; that when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4-methylphenyl; that when A is methyl and B is hydrogen, then T is not 4-bromophenyl; that when A is tert-butyl and B is bromo, then T is not 4-chlorophenyl;
A is Ci-6-alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is hydrogen, methyl, ethyl, n-propyl, n-butyl, halogenated d-6-alkyl, Cι.6-acyl or . 6-alkoxycarbonyl;
as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
2. A compound according to claim 1, wherein
T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
with the proviso: that when A is methyl and B is hydrogen, then T is not phenyl; that when A is methyl and B is 2,2,2-trichloroethyl, then T is not 4-methylphenyl; that when A is methyl and B is hydrogen, then T is not 4-bromophenyl; that when A is tert-butyl and B is bromo, then T is not 4-chlorophenyl;
A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is selected from hydrogen, methyl, ethyl, n-propyl, n-butyl, 2,2,2-trichloroethyl, acetyl and carbethoxy.
3. A compound of claim 1 selected from the group consisting of: 4-cUoro-N-(4-methyl-l,3-thiazol-2-yl)benzenesulfonamide, 3-chloro-2-methyl-N-(4-methyl- l,3-t azol-2-yl)benzenesulfonamide,
3-cWoro-2-methyl-N-[4-methyl-5-(2,2,2-tricMoroethyl)-l,3-thiazol-2- yl]benzenesulfonamide, N-[4-methyl-5-(2,2,2-tricUoroethyl)-l,3-thiazol-2-yl]-2,4,6-trichlorobenzene- sulfonamide, 3-cUoro-N-(5-ethyl-4-methyl-l,3-tlύazol-2-yl)-2-methylbenzenesulfonamide5
3-cUoro-2-methyl-N-(4-methyl-5-ρroρyl-l,3-thiazol-2-yl)benzenesulfonamide, 3-cUoro-N-(4-ethyl-l,3-t azol-2-yl)-2-methylbenzenesulfonamide, 3-cmoro-N-(4-ethyl-5-methyl-l,3-t^
3-cUoro-2-methyl-N-(4-propyl-l,3-thiazol-2-yl)benzenesulfonamide, 3 -chloro-N-(4-isopropyl- 1 , 3 -thiazol-2-yl)-2-memylbenzenesulfonamide,
N-(4-butyl-l,3-tMazol-2-yl)-3-cMoro-2-methylbenzenesulfonarnide, N-(5-butyl-4-methyl-l,3-thiazol-2-yl)-2,4-dichloro-6-r amide, N-(4-tert-butyl-l,3-tMazol-2-yl)-3-cMoro-2-methylbenzenesulfonamide, ethyl 3-(2-{[(2,4-dicWoro-6-methylphenyl)s fonyl]ammo}-l,3-thiazol-4-yl)-3- methylbutanoate,
2,4-o chloro-6-methyl-N-(4-pentyl-l,3-thiazol-2-yl)benzenesulfonaπύ 3-c oro-2-methyl-N-(4-vinyl-l,3-t azol-2-yl)benzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tltiazol-2-yl)-4-cUorobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-3-chloro-2-methylbenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)[l, r-biphenyl]-4-sulfonamide,
N-(5-acetyl-4-meihyl-l,3-tlnazol-2-yl)-4-(3-chloro-2-cyanophenoxy)benzene- sulfonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-propylbenzenesulfonamide, N-(5-acetyl-4-methyl- l,3-thiazol-2-yl)-2,4,6-tricldorobenzenesulfonamide, N-(5-acetyl-4-methyl- 1 ,3 -tl azol-2-yl)-2,4-o-icUoro-6-methylbenzenesulfon- amide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,4,5-tricMorobenzenes fonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-4-bromo-5-cUoro-2-tMenylsulfonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-bromo-2,5-difluoro-2-benzenesulfon- amide,
N-(5-acetyl-4-methyl- l,3-thiazol-2-yl)-2,6-(hcUorobenzenesulfonamide, N-(5-carbethoxy-4-methyl-l,3-tMazol-2-yl)-3-cUoro-2-methylbenzene- sulfonamide, N-(5-carbethoxy-4-methyl- l,3-thiazol-2-yl)[ 1, 1 '-biphenyl]-4-sulfonamide, N-(5-carbethoxy-4-methyl-l,3-tMazol-2-yl)-4-propylbenzenesulfonamide,
N-(5-carbethoxy-4-methyl-l,3-tltiazol-2-yl)-2,4-ά chloro-6-methylbenzene- sulfonamide, N-(5-carbethoxy-4-methyl-l,3-tHazol-2-yl)-2,4,6-tricWorobenzenesulfo
4. A compound according to anyone of claims 1-3, for medical use.
5. A process for the preparation of a compound according t< least one of the following steps: a) sulfonamide coupling by reacting a 2-aminothiazole with a sulfonylchloride in the presence of a base, b) sulfonamide coupling by reacting a 2-aminothiazole derivative with a sulfonylchloride in the presence of a base, c) saponification by treatment of a carboxylic acid ester with aqueous hydroxide, d) amide coupling by reacting a carboxylic acid with an amine in the presence of EDCI, e) formation of a thiazole ring by reacting an optionally substituted thiourea with an α-haloketone. f) formation of a thiazole ring by reacting a thiourea with a ketone, g) reduction of an ester with lithium aluminium hydride, h) conversion of an alcohol to a bromide with triphenylphosphine and carbon tetrabromide, i) elimination of a bromide with a base to an alkene.
6. A method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hypeimsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders, said method comprising administering to a mammal, including man, in need of such treatment an effective amount of a compound of the formula (I)
Figure imgf000040_0001
wherein T is an aryl ring or heteroaryl ring, optionally independently wherein n is an integer 0-5, and R is hydrogen, Ci-β-alkyl, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
A is Cι-6-alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is hydrogen, halogen, Ci-β-alkyl, halogenated Cι-6-alkyl, -6-acyl or Ci-β- alkoxycarbonyl;
as well as pharmaceutically acceptable salts, hydrates and solvates thereof.
7. A method according to claim 6, wherein
T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3 -(ethyl 3-methylbutanoate);
B is selected from hydrogen, bromo, methyl, ethyl, n-propyl, n-butyl, 2,2,2- trichloroethyl, acetyl and carbethoxy.
8. A method according to claim 6-7, wherein the compound is selected from: 4-chloro-N-(4-methyl- 1 ,3 -thiazol-2-yl)benzenesulfonamide,
N-(4-methyl-l,3-thiazol-2-yl)benzenesulfonamide,
3-chloro-2-methyl-N-(4-memyl-l,3-t azol-2-yl)berιzenesulfonamide,
4-cHoro-N-[4-me l-5-(2,2,2-trichloroethyl)-l,3-thiazol-2- yl]benzenesulfonamide, 3-c oro-2-methyl-N-[4-me l-5-(2,2,2-tricMoroethyl)-l,3-thiazol-2- yl]benzenesulfonamide, N-[4-methyl-5-(2,2,2-tricMoroethyl)-l,3-thiazol-2-yl]- sulfonamide, 3-cMoro-N-(5-ethyl-4-methyl-l,3-tMazol-2-yl)-2-methylbenzenesulfonamide, 3-cl oro-2-methyl-N-(4-methyl-5-ρropyl-l,3-t azol-2-yl)benzenesulfonarm 3-cUoro-N-(4-ethyl-l,3-tlύazol-2-yl)-2-methylbenzenesulfonamide,
3-cMoro-N-(4-ethyl-5-methyl-l,3-trήazol-2-yl)-2-methylbenzenesulfonamide, 3 -chloro-2-methyl-N-(4-propyl- 1 ,3 -thiazol-2-yl)benzenesulfonamide, 3-chloro-N-(4-isopropyl- l,3-thiazol-2-yl)-2-methylbe---zenesulfonamide, N-(4-butyl- 1 ,3 -thiazol-2-yl)-3 -chloro-2-methylbenzenesulfonamide, N-(5-butyl-4-methyl-l,3-thiazol-2-yl)-2,4-oichloro-6-methylbenzenesulfon- amide, N-(4-tert-butyl-l,3-tMazol-2-yl)-3-cWoro-2-memylbenzenesulfonamide, ethyl 3-(2- [(2,4-dicWoro-6-methylphenyl)sulfonyl]ammo}-l,3-tMazol-4-yl)-3- methylbutanoate, 2,4-dichloro-6-methyl-N-(4-pentyl- 1 ,3 -thiazol-2-yl)benzenesulfonamide,
3 -chloro-2-methyl-N-(4-vinyl- 1 ,3 -thiazol-2-yl)benzenesulfonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-cUorobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-3-cHoro-2-methylbenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)[l, -biphenyl]-4-s fonamide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-(3-chloro-2-cyanophenόxy)benzene- sulfonamide, N-(5-acetyl-4-methyl- 1 ,3 -thiazol-2-yl)-4-propylbenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-u iazol-2-yl)-2,4,6-tricUorobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-2,4-dichloro-6-memylbenzenesulfon- amide,
N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-2,4,5-trichlorobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-t azol-2-yl)-4-bromo-5-cMoro-2-t enylsulfonan^ N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-4-bromo-2,5-difluoro-2-berizenesulfon- amide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,6-(hcMorobenzenesulfonamide, N-(5-carbethoxy-4-memyl-l,3-thiazol-2-yl)-3-chloro-2 sulfonamide, N-(5-carbethoxy-4-methyl-l,3-tMazol-2-yl)[l,l'-biphenyl]-4-sulfonamide, N-(5-carbethoxy-4-methyl- l,3-tMazol-2-yl)-4-propylbenzenesulfonamide, N-(5-carbethoxy-4-methyl- 1 ,3 -tMazol-2-yl)-2,4-(hchloro-6-methylbenzene- sulfonamide, N-(5-carbethoxy-4-methyl- 1 ,3 -thiazol-2-yl)-2,4,6-trichlorobenzenesulfonamide, N-[5-bromo-4-(tert-butyl)-l,3-tMazol-2-yl]-4-cWorobenzenesulfonamide.
9. The use of a compound of the formula (I)
Figure imgf000043_0001
wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, Cι.6-alkyl, halogen, aryl or aryloxy, wherein the aryloxy residue can further be optionally substituted in one or more positions independently of each other by cyano and halogen;
A is Ci-β-alkyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is hydrogen, halogen, Cι-6-alkyl, halogenated Cι-6-alkyl, -e-acyl or Cι.6- alkoxycarbonyl;
as well as pharmaceutically acceptable salts, hydrates and solvates thereof, in the manufacture of a medicament for the prevention, man diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hypermsulinemia, osteoporosis, tuberculosis, dementia, depression, virus diseases and inflammatory disorders.
10. The use according to claim 9, wherein
T is selected from 4-bromo-5-chloro-2-thienyl and phenyl substituted with one or more of bromo, chloro, 3-chloro-2-cyanophenoxy, fluoro, methyl, phenyl, n-propyl;
A is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, vinyl or 3-(ethyl 3-methylbutanoate);
B is selected from hydrogen, bromo, methyl, ethyl, n-propyl, n-butyl, 2,2,2- trichloroethyl, acetyl and carbethoxy.
11. The use according to claim 9-10, wherein the compound is selected from: 4-cUoro-N-(4-methyl-l,3-tltiazol-2-yl)berιzenesulfonamide, N-(4-methyl-l,3-thiazol-2-yl)benzenesulfonamide, 3-cMoro-2-methyl-N-(4-methyl-l,3-tMazol-2-yl)benzenesulfonamide,
4-cWoro-N-[4-methyl-5-(2,2,2-tricWoroethyl)-l,3-thiazol-2- yl]benzenesulfonamide, 3-cmoro-2-methyl-N-[4-methyl-5-(2,2,2-trichloroethyl)- l,3-thiazol-2- yl]benzenesulfonamide, N-[4-memyl-5-(2,2,2-tricWoroe l)-l,3-tMazol-2-yl]-2,4,6-tricWorobenz sulfonamide, 3-cMoro-N-(5-ethyl-4-methyl-l,3-thiazol-2-yl)-2-methylbenzenesulfonamide, 3-cMoro-2-methyl-N-(4-methyl-5-propyl-l,3-tMazol-2-yl)benzenesulfonamide, 3 -chloro-N-(4-ethyl- 1 , 3 -thiazol-2-yl)-2-methylbenzenesulfonamide, 3-chloro-N-(4-ethyl-5-methyl- l,3-thiazol-2-yl)-2-methylbenzenesulfonamide,
3-cMoro-2-methyl-N-(4-propyl-l,3-thiazol-2-yl)benzenesulfonamide, 3-cWoro-N-(4-isopropyl-l,3-thiazol-2-yl)-2-methylbei
N-(4-butyl-l,3-tMazol-2-yl)-3-cWoro-2-methylbenzenesulfonamide,
N-(5-butyl-4-methyl-l,3-tMazol-2-yl)-2,4-d cMoro-6-methylbenzenesulfon- amide, N-(4-tert-butyl-l,3-tMazol-2-yl)-3-chloro-2-methylberι-zenesulfonamide, e yl 3-(2-{[(2,4-ώctøoro-6-methylphenyl)su methylbutanoate, 2,4-dicMoro-6-me1hyl-N-(4-pentyl-l,3-tMazol-2-yl)benzenesulfonamide, 3-cMoro-2-methyl-N-(4-vinyl-l,3-tMazol-2-yl)benzenesdfonamide, N-(5-acetyl-4-methyl-l,3-tlύazol-2-yl)-4-cWoroberιzenesulfonamide,
N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-3-clιloro-2-methylbenzenesulfonamide,
N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)[l,r-biphenyl]-4-sulfonamide,
N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-4-(3-chloro-2-cyanophenoxy)benzene- sulfonamide, N-(5-acetyl-4-methyl- l,3-tMazol-2-yl)-4-propylberizenesulfonamide,
N-(5-acetyl-4-memyl-l,3-tMazol-2-yl)-2,4,6-tricWoroberιzenesulfonarnide, N-(5-acetyl-4-methyl-l,3-tlύazol-2-yl)-2,4-ά cUoro-6-methylbenzenesulfon- amide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-2,4,5-tric orobenzenesulfonamide, N-(5-acetyl-4-methyl-l,3-tMazol-2-yl)-4-bromo-5-chloro-2-tMenylsulfonamide,
N-(5-acetyl-4-methyl-r,3-thiazol-2-yl)-4-bromo-2,5-d uoro-2-benzenesulfon- amide, N-(5-acetyl-4-methyl-l,3-thiazol-2-yl)-2,6-o c orobenzenesulfonamide, N-(5-carbethoxy-4-methyl-l,3-t azol-2-yl)-3-cldoro-2-methylbenzene- sulfonamide,
N-(5-carbethoxy-4-methyl-l,3-t azol-2-yl)[l,r-biρhenyl]-4-s fonamide, N-(5-carbethoxy-4-methyl- l,3-thiazol-2-yl)-4-propylbenzenesulfonamide, N-(5-carbethoxy-4-methyl-l,3-tWazol-2-yl)-2,4-dicMoro-6-methylbenzene- ' sulfonamide, N-(5-carbethoxy-4-methyl-l,3-t azol-2-yl)-2,4,6-tricMorobenzenesulfonar^
N-[5-bromo-4-(tert-butyl)-l,3-tMazol-2-yl]-4-cMoroberιzenesulfonamide.
2. A pharmaceutical composition comprising at least one compound of the formula ) as defined in any of the claims 1-3, and a pharmaceutically acceptable carrier.
PCT/SE2001/001156 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 WO2001090091A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU6445601A AU6445601A (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NZ522507A NZ522507A (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US10/276,954 US7125900B2 (en) 2000-05-22 2001-05-22 Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
IL15267001A IL152670A0 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP01938885A EP1283833A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA002408142A CA2408142C (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2001586279A JP2003534337A (en) 2000-05-22 2001-05-22 Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1
NO20025587A NO323779B1 (en) 2000-05-22 2002-11-21 Inhibitors for 11-beta-hydroxy steroid dehydrogenase type 1
US11/511,224 US20060287374A1 (en) 2000-05-22 2006-08-29 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0001899-4 2000-05-22
SE0001899A SE0001899D0 (en) 2000-05-22 2000-05-22 New compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/511,224 Division US20060287374A1 (en) 2000-05-22 2006-08-29 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Publications (2)

Publication Number Publication Date
WO2001090091A1 true WO2001090091A1 (en) 2001-11-29
WO2001090091A8 WO2001090091A8 (en) 2002-07-25

Family

ID=20279781

Family Applications (5)

Application Number Title Priority Date Filing Date
PCT/SE2001/001154 WO2001090093A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001156 WO2001090091A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001155 WO2001090090A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001157 WO2001090094A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001158 WO2001090092A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001154 WO2001090093A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/SE2001/001155 WO2001090090A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001157 WO2001090094A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PCT/SE2001/001158 WO2001090092A1 (en) 2000-05-22 2001-05-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Country Status (24)

Country Link
US (7) US7132436B2 (en)
EP (4) EP1283834B1 (en)
JP (4) JP2003534338A (en)
KR (4) KR20030011341A (en)
CN (4) CN1437588A (en)
AR (1) AR033534A1 (en)
AT (2) ATE443055T1 (en)
AU (6) AU6283101A (en)
BR (1) BR0111099A (en)
CA (4) CA2409697C (en)
DE (3) DE60143293D1 (en)
EA (1) EA005274B1 (en)
ES (1) ES2333846T3 (en)
HK (1) HK1056878A1 (en)
HU (1) HUP0302435A3 (en)
IL (4) IL152669A0 (en)
MX (1) MXPA02011632A (en)
NO (4) NO323832B1 (en)
NZ (4) NZ522591A (en)
PE (1) PE20020100A1 (en)
PL (1) PL360137A1 (en)
SE (1) SE0001899D0 (en)
WO (5) WO2001090093A1 (en)
ZA (4) ZA200209359B (en)

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043999A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003089419A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab New 2-substituted -1,3-thiazole compounds
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
WO2004033427A1 (en) * 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004112781A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab New use ii
WO2004113310A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2006000371A2 (en) 2004-06-28 2006-01-05 F.Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
WO2005110980A3 (en) * 2004-04-14 2006-02-23 Amgen Inc Aryl sulfones and uses related thereto
US7030135B2 (en) 2000-05-22 2006-04-18 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7074788B2 (en) 2001-11-22 2006-07-11 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7094792B2 (en) 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
US7309715B2 (en) 2002-10-24 2007-12-18 Sterix Limited Compound
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
US7358238B2 (en) 2003-04-11 2008-04-15 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US7365075B2 (en) 2003-12-22 2008-04-29 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
WO2008101886A1 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101914A2 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101885A1 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
WO2009001817A1 (en) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. COMPOUND HAVING 11β-HSD1 INHIBITORY ACTIVITY
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
US7495012B2 (en) 2004-04-20 2009-02-24 Amgen Inc. Arylsulfonamides and uses related thereto
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
AU2007205749B2 (en) * 2001-11-22 2009-04-23 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
EP2239012A2 (en) 2003-04-11 2010-10-13 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted amides
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
CN111620837A (en) * 2020-06-29 2020-09-04 郑州大学 Cedar ketone thiazole amide compound, and preparation method and application thereof
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001276378A1 (en) * 2000-07-05 2002-01-14 Bayer Aktiengesellschaft Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
WO2003044000A1 (en) * 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200400709A1 (en) * 2001-11-22 2004-12-30 Биовитрум Аб INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
WO2003061655A1 (en) 2002-01-16 2003-07-31 University Of Virginia Patent Foundation 2-aminothiazole allosteric enhancers of a1 adenosine receptors
EP1474139B1 (en) 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
US7338969B2 (en) * 2002-03-08 2008-03-04 Quonova, Llc Modulation of pathogenicity
EP2141143A3 (en) * 2002-03-29 2010-05-05 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4 protected piperazines
US20030198965A1 (en) 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
AR040241A1 (en) * 2002-06-10 2005-03-23 Merck & Co Inc INHIBITORS OF 11-BETA-HYDROXIESTEROID DEHYDROGRENASE 1 FOR THE TREATMENT OF DIABETES OBESITY AND DISLIPIDEMIA
AU2003275195A1 (en) * 2002-09-18 2004-04-08 Hartmut M. Hanauske-Abel INHIBITORS OF 11Beta-HYDROXYSTEROID DEHYDROGENASE AND USES THEREFOR
KR20050059294A (en) 2002-10-24 2005-06-17 스테릭스 리미티드 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
AU2003276458A1 (en) * 2002-11-07 2004-06-07 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
GB0226602D0 (en) * 2002-11-14 2002-12-24 Novartis Ag Organic compounds
AR041952A1 (en) * 2002-11-14 2005-06-01 Novartis Ag N-SULFONYLAMINOTIAZOL
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Triazole Derivatives As Inhibitors Of 11-Beta -Hydroxysteriod Dehydrogenase-1
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
FR2849598B1 (en) * 2003-01-07 2006-09-22 Merck Sante Sas USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF CELLS OF THE LANGERHANS ISLANDS
FR2849599B1 (en) * 2003-01-07 2006-12-29 Merck Sante Sas USE OF KYNURENINE-3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
EP1785424A3 (en) * 2003-04-11 2009-12-23 High Point Pharmaceuticals, LLC Fused 1,2,4-triazoles and pharmaceutical uses thereof
CA2526712A1 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
SE0301885D0 (en) * 2003-06-25 2003-06-25 Biovitrum Ab New use IV
SE0301882D0 (en) * 2003-06-25 2003-06-25 Biovitrum Ab New use I
SE0301884D0 (en) * 2003-06-25 2003-06-25 Biovitrum Ab New use III
GB0324792D0 (en) 2003-10-23 2003-11-26 Sterix Ltd Compound
GB0325745D0 (en) * 2003-11-05 2003-12-10 Astrazeneca Ab Chemical compounds
CN1910161A (en) 2004-01-26 2007-02-07 默克公司 Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase type 1
JP2007261945A (en) * 2004-04-07 2007-10-11 Taisho Pharmaceut Co Ltd Thiazole derivative
GB0408771D0 (en) * 2004-04-20 2004-05-26 Sterix Ltd Compound
JP5014983B2 (en) 2004-05-07 2012-08-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
EP1791822A1 (en) * 2004-08-05 2007-06-06 F.Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles
DE602005017159D1 (en) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv OXYSTEROID DEHYDROGENASE INHIBITORS
EP1786774B1 (en) 2004-08-30 2009-10-14 Janssen Pharmaceutica N.V. Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
UA87328C2 (en) 2004-08-30 2009-07-10 Янссен Фармацевтика Н.В. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
CA2581865C (en) * 2004-09-29 2010-04-20 F. Hoffmann-La Roche Ag Indazolone derivatives as 11b-hsd1 inhibitors
EP1799647A1 (en) * 2004-10-04 2007-06-27 F.Hoffmann-La Roche Ag Alkil-pyridines as 11-beta inhibitors for diabetes
WO2006040178A1 (en) * 2004-10-14 2006-04-20 Abbott Gmbh & Co.Kg Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine d3 receptor
JP2008517930A (en) 2004-10-21 2008-05-29 トランス テック ファーマ，インコーポレイテッド Bissulfonamide compounds, compositions, and methods of use as agonists of GalR1
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1666467A1 (en) * 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
WO2006051662A1 (en) * 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
WO2006059507A1 (en) * 2004-11-30 2006-06-08 Sankyo Company, Limited 11β-HSD1 ANTISENSE COMPOUND
EP1888544A2 (en) * 2004-12-17 2008-02-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
JP4250675B2 (en) * 2005-06-16 2009-04-08 ファイザー・インク N- (Pyridin-2-yl) -sulfonamide derivative
WO2006134481A1 (en) * 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
JP2007099659A (en) * 2005-10-03 2007-04-19 Toray Fine Chemicals Co Ltd Method for producing piperazinecarboxylic acid ester
WO2007047474A2 (en) * 2005-10-12 2007-04-26 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
US20070110802A1 (en) * 2005-11-15 2007-05-17 Janan Jona Wet granulation process
CA2633653A1 (en) 2005-12-21 2007-07-05 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
ATE473210T1 (en) * 2006-04-24 2010-07-15 Lilly Co Eli SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE 1
CA2649111C (en) * 2006-04-24 2013-09-10 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CN101096363B (en) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-three-substituted thiazole compound, preparation method, medicament composition and pharmacy use thereof
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
CN101668524B (en) * 2007-02-12 2012-10-24 阿斯利康(瑞典)有限公司 Pyrazole derivatives as 11-beta-hsd1 inhibitors
JP5361857B2 (en) 2007-03-23 2013-12-04 ファイザー・リミテッド Ion channel inhibitors
CA2683852A1 (en) * 2007-04-11 2008-10-23 High Point Pharmaceuticals, Llc Novel compounds
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh New crystalline hydrate form of dodecanedioic acid 4-((2S,3R)-3-((S)-3-(4-fluoro-phenyl)-3-hydroxy-propyl)-2-(4-methoxy-phenyl)-4-oxo-azetidin-1-yl)-benzylamide ((2S,3R,4R,5R)-pentahydroxy-hexyl)-amide useful e.g. to treat hyperlipidemia
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR200452117Y1 (en) * 2008-11-10 2011-02-08 대성공업주식회사 Brake wire holder wheel chair
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2350077B1 (en) 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. INHIBITING COMPOUNDS OF 11BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 1.
EP2470552B1 (en) 2009-08-26 2013-11-13 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683702B1 (en) 2011-03-08 2014-12-24 Sanofi New substituted phenyl oxathiazine derivatives, method for their manufacture, medicines containing these compounds and their application
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103204824B (en) * 2012-01-12 2015-04-08 清华大学深圳研究生院 2-aminothiazole-4-amide derivative, its preparation method and application
CN105017135A (en) * 2015-07-19 2015-11-04 佛山市赛维斯医药科技有限公司 11 beta-HSD1 inhibitor with dipyridyl-tert-alcohol structure and its preparation method and use
CN105001152A (en) * 2015-07-19 2015-10-28 佛山市赛维斯医药科技有限公司 11 beta-HSD1 inhibitor of dimethylamino bipyridine tertiary alcohol structure and application thereof
CN107663204A (en) * 2016-10-19 2018-02-06 首都医科大学附属北京世纪坛医院 A kind for the treatment of tuberculosis application of compound
US11505547B2 (en) 2017-11-30 2022-11-22 Step Pharma S.A.S. Compounds
WO2019106156A1 (en) * 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
CN108358869B (en) * 2018-03-27 2019-09-10 河北师范大学 A kind of N- benzothiazolyl benzsulfamide analog derivative, Preparation method and use
CN108659219B (en) * 2018-06-08 2021-02-09 扬州大学 Preparation method of polyaniline
CN109748831A (en) * 2018-12-17 2019-05-14 南通正达农化有限公司 A kind of preparation method of trifluoromethanesulfonic acid trifluoro ethyl ester
MX2022001828A (en) 2019-08-14 2022-06-08 Vertex Pharma Crystalline forms of cftr modulators.
TW202120517A (en) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 Process of making cftr modulators
TW202115092A (en) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 Modulators of cystic fibrosis transmembrane conductance regulator
EP4225750A1 (en) * 2020-10-07 2023-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN112451514A (en) * 2020-11-26 2021-03-09 江西农业大学 Dihydromyricetin nano-selenium and preparation method and application thereof
CN113461635A (en) * 2021-07-07 2021-10-01 上海毕得医药科技股份有限公司 4- (2-chloroethyl) thiazole-2-carboxylic acid ethyl ester and preparation method and application thereof
JP2024534799A (en) * 2021-08-20 2024-09-26 エナンタ ファーマシューティカルズ インコーポレイテッド 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2362087A (en) * 1938-06-03 1944-11-07 May & Baker Ltd Sulphanilamido-thiazoles
JPH07149746A (en) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc New 2-substituted aminothiazole derivative
JPH07149745A (en) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc New 2-aminothiazole derivative
WO1997007789A1 (en) * 1995-08-29 1997-03-06 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
EP0819681A2 (en) * 1996-07-19 1998-01-21 F. Hoffmann-La Roche Ag N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use
WO1999028306A1 (en) * 1997-11-27 1999-06-10 Pharmacia & Upjohn S.P.A. Benzenesulfonamide compounds

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB620654A (en) * 1939-10-03 1949-03-29 Chinoin Gyogyszer Es Vegyeszet A process for the preparation of sulphonamide derivatives of 2-amino-thiazole
US2611770A (en) 1949-04-16 1952-09-23 American Cyanamid Co N-(2-thiazolyl)-2-hydroxypyridine-5-sulfonamides
GB822947A (en) 1957-01-25 1959-11-04 Smith & Nephew Improvements in and relating to sulphonamides
DE1620508A1 (en) * 1965-07-23 1969-09-18 Thomae Gmbh Dr K Process for the preparation of new 4,5,6,7-tetrahydrothiazolo- [5,4-c] -pyridines
CA1088049A (en) 1975-06-03 1980-10-21 Takashi Masugi 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof
FR2384498A1 (en) * 1975-11-26 1978-10-20 Parcor Antibacterial, antifungal and hypoglycaemic sulphonamido thiazole(s) - prepd. from a phenyl sulphonamide and an isothiocyanato butyne
EP0246749A3 (en) * 1986-05-17 1988-08-31 AgrEvo UK Limited Triazole herbicides
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
JPH021483A (en) 1988-03-10 1990-01-05 Nippon Tokushu Noyaku Seizo Kk Agricultural fungicide
JPH078863B2 (en) 1989-09-21 1995-02-01 久光製薬株式会社 Novel diphenylthiazole derivative
EP0532239B1 (en) * 1991-09-10 1995-12-13 Zeneca Limited Benzenesulphonamide derivatives as 5-lipoxygenase inhibitors
JPH0670024B2 (en) 1993-04-13 1994-09-07 塩野義製薬株式会社 Method for producing glutaconate derivative
US6030991A (en) 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
JPH07309757A (en) * 1994-05-18 1995-11-28 Asahi Chem Ind Co Ltd Beta-amyloid protein neurocyte toxicity reducing agent
SI0779810T1 (en) 1994-08-09 2003-12-31 Cortendo Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
SE505391C2 (en) 1995-05-30 1997-08-18 Cortendo Ab Use of cortisol agonists to prepare a system for diagnosing the metabolic syndrome
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
WO1997047299A1 (en) * 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
JP2001503037A (en) 1996-10-16 2001-03-06 アメリカン・サイアナミド・カンパニー Preparation and use of ortho-sulfonamidoheteroarylhydroxamic acids as inhibitors of matrix metalloproteinases and tace
DZ2376A1 (en) 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
SE9700642D0 (en) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Means and ways of preventing and treating the metabolic syndrome
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
ES2237919T4 (en) 1998-06-18 2007-05-01 Bristol-Myers Squibb Company AMINOTIAZOL INHIBITORS REPLACED WITH CARBON OF CYCLINE DEPENDENT KINASES.
CN1332943C (en) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use pharmaceutical preparations comprising them
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
IT1317735B1 (en) 2000-01-26 2003-07-15 Nicox Sa SALTS OF ANTIMICROBIAL AGENTS.
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2002213048A1 (en) 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
EA200400709A1 (en) 2001-11-22 2004-12-30 Биовитрум Аб INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
EA200400708A1 (en) 2001-11-22 2004-10-28 Биовитрум Аб INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
RS44304A (en) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
PL370111A1 (en) 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2362087A (en) * 1938-06-03 1944-11-07 May & Baker Ltd Sulphanilamido-thiazoles
JPH07149746A (en) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc New 2-substituted aminothiazole derivative
JPH07149745A (en) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc New 2-aminothiazole derivative
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
WO1997007789A1 (en) * 1995-08-29 1997-03-06 The University Of Edinburgh Regulation of intracellular glucocorticoid concentrations
EP0819681A2 (en) * 1996-07-19 1998-01-21 F. Hoffmann-La Roche Ag N-(4-Aryl-thiazol-2-yl)-sulfonamides and their use
WO1999028306A1 (en) * 1997-11-27 1999-06-10 Pharmacia & Upjohn S.P.A. Benzenesulfonamide compounds

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ARCH. PHARM., vol. 288, 1955, pages 321 - 336 *
CHEMICAL ABSTRACTS, 1957, Columbus, Ohio, US; abstract no. 6646D, HANS WOJAHN: "Bromination of sulfapyrimidine and sulfathiazole compounds. II." XP002945577 *
DATABASE CAOLD [online] BEREZHINSKAYA V.V.: "Hypoglycemic activity in relation to chem. structure of potential oral antidiabetic substances - (I) 1-sulfonyl-3-alkylureas, (II) Analogs of 1-sulfonyl-3-alkylureas, (III) 2-Benzene-sulfonamido-5-alkyl-1,3,4-thiadiazole and-oxadiazoles", XP002945576, accession no. STN Database accession no. CA57:3567g *
DATABASE CAPLUS [online] BOBERG FRIEDRICH ET AL.: "Reaction of thioxo compounds with N-chloramidines. VI. Reaction of thioquinolone, dihydrothiazolethione and dihydroisothiazole thione with sodium N-chlorobenzenesulfonamides", XP002945581, accession no. STN Database accession no. 1996:420288 *
DATABASE CAPLUS [online] HISAMITSU PHARMACEUTICAL CO.; "Preparation of 2-(substituted amino)thiazole derivatives as esterase inhibitors", XP002945580, accession no. STN Database accession no. 1995:818696 *
DATABASE CAPLUS [online] HISAMITSU PHARMACEUTICAL CO.; "Preparation of 2-aminothiazole derivatives as esterase inhibitors", XP002945579, accession no. STN Database accession no. 1995:867676 *
DATABASE CAPLUS [online] KRASOVSKII V.A. ET AL.: "Alkylation of aminothiazoles. VII. Alkylation of 2-aminothiazole and 4-methyl-2aminothiazole by tert-butyl alcohol", XP002945578, accession no. STN Database accession no. 1969:115051 *
DATABASE CHEMCATS [online] ASINEX COMPOUND COLLECTION; 10 May 2001 (2001-05-10), "5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-, ethyl ester", XP002945565, accession no. STN Database accession no. 2001:67657 *
DATABASE CHEMCATS [online] CHEMDIV, INC. PRODUCT LIBRARY; 26 April 2001 (2001-04-26), "5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino-, ethyl ester", XP002945575, accession no. STN Database accession no. 2001:444469 *
DATABASE CHEMCATS [online] PHARMA LIBRARY COLLECTION; 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 2-(((4-chlorophenyl)sulfonyl)amino-4-methyl-, ethyl ester", XP002945574, accession no. STN Database accession no. 2001:19109 *
KHIM. GETEROTSIKL. SOEDIN., no. 1, 1969, pages 56 - 58 *
PHOSPHORUS, SULFUR SILICON RELAT. ELEM., vol. 108, no. 1-4, 1996, pages 203 - 220 *

Cited By (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030135B2 (en) 2000-05-22 2006-04-18 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7132436B2 (en) 2000-05-22 2006-11-07 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7125900B2 (en) * 2000-05-22 2006-10-24 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7618961B2 (en) 2000-05-22 2009-11-17 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2007205749B2 (en) * 2001-11-22 2009-04-23 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7671051B2 (en) 2001-11-22 2010-03-02 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2003043999A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7094792B2 (en) 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7074788B2 (en) 2001-11-22 2006-07-11 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003089419A1 (en) * 2002-04-19 2003-10-30 Astrazeneca Ab New 2-substituted -1,3-thiazole compounds
WO2004002986A2 (en) 2002-06-28 2004-01-08 Banyu Pharmaceutical Co., Ltd. Novel benzimidazole derivatives
WO2004033427A1 (en) * 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
US7786152B2 (en) 2002-10-24 2010-08-31 Sterix Limited Compound
US7309715B2 (en) 2002-10-24 2007-12-18 Sterix Limited Compound
US7358238B2 (en) 2003-04-11 2008-04-15 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP2239012A2 (en) 2003-04-11 2010-10-13 High Point Pharmaceuticals, LLC Pharmaceutical use of substituted amides
US7501405B2 (en) 2003-04-11 2009-03-10 High Point Pharmaceuticals, Llc Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2004113310A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
WO2004112781A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab New use ii
WO2005028438A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US7365075B2 (en) 2003-12-22 2008-04-29 Amgen Inc. Aryl sulfonamide compounds and uses related thereto
EP2088154A1 (en) 2004-03-09 2009-08-12 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7754890B2 (en) 2004-04-14 2010-07-13 Amgen Inc. Arylsulfones and uses related thereto
US7402704B2 (en) 2004-04-14 2008-07-22 Amgen Inc. Arylsulfones and uses related thereto
WO2005110980A3 (en) * 2004-04-14 2006-02-23 Amgen Inc Aryl sulfones and uses related thereto
US7834047B2 (en) 2004-04-20 2010-11-16 Amgen Inc. Arylsulfonamides and uses related thereto
US7495012B2 (en) 2004-04-20 2009-02-24 Amgen Inc. Arylsulfonamides and uses related thereto
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7807700B2 (en) 2004-05-24 2010-10-05 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2006000371A2 (en) 2004-06-28 2006-01-05 F.Hoffmann-La Roche Ag Pyrimidine derivatives as 11beta-hsd1 inhibitors
WO2006000371A3 (en) * 2004-06-28 2006-04-27 Hoffmann La Roche Pyrimidine derivatives as 11beta-hsd1 inhibitors
US7507733B2 (en) 2004-06-28 2009-03-24 Hoffmann-La Roche Inc. 11b-HSD1 inhibitors for the treatment of diabetes
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
WO2006129826A1 (en) 2005-05-30 2006-12-07 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2007018248A1 (en) 2005-08-10 2007-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone compound
WO2007024004A1 (en) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
WO2007029847A1 (en) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. Bicyclic aromatic substituted pyridone derivative
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
WO2007049798A1 (en) 2005-10-27 2007-05-03 Banyu Pharmaceutical Co., Ltd. Novel benzoxathiin derivative
WO2007055418A1 (en) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. Aza-substituted spiro derivative
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
EP2698157A1 (en) 2006-09-22 2014-02-19 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008101886A1 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101914A2 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008101885A1 (en) 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
WO2008120653A1 (en) 2007-04-02 2008-10-09 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
EP2998314A1 (en) 2007-06-04 2016-03-23 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009001817A1 (en) 2007-06-27 2008-12-31 Taisho Pharmaceutical Co., Ltd. COMPOUND HAVING 11β-HSD1 INHIBITORY ACTIVITY
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2009110510A1 (en) 2008-03-06 2009-09-11 萬有製薬株式会社 Alkylaminopyridine derivative
WO2009119726A1 (en) 2008-03-28 2009-10-01 萬有製薬株式会社 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
EP2810951A2 (en) 2008-06-04 2014-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (en) 2008-06-19 2009-12-23 萬有製薬株式会社 Spirodiamine-diarylketoxime derivative
EP3241839A1 (en) 2008-07-16 2017-11-08 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051236A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010059618A1 (en) 2008-11-21 2010-05-27 High Point Pharmaceuticals, Llc Adamantyl benzamide compounds
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
EP2923706A1 (en) 2009-12-03 2015-09-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2011069038A2 (en) 2009-12-03 2011-06-09 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2011106273A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
US8513430B2 (en) 2010-07-27 2013-08-20 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators
EP3243385A1 (en) 2011-02-25 2017-11-15 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012116145A1 (en) 2011-02-25 2012-08-30 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
WO2012118972A2 (en) 2011-03-01 2012-09-07 Synegy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2013059222A1 (en) 2011-10-19 2013-04-25 Merck Sharp & Dohme Corp. 2-pyridyloxy-4-nitrile orexin receptor antagonists
EP3708179A1 (en) 2012-03-15 2020-09-16 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en) 2012-03-15 2024-01-24 Bausch Health Ireland Limited Formulations of guanylate cyclase c agonists and methods of use
WO2013138352A1 (en) 2012-03-15 2013-09-19 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051725A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016030534A1 (en) 2014-08-29 2016-03-03 Tes Pharma S.R.L. INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
US11254644B2 (en) 2014-08-29 2022-02-22 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
US9708272B2 (en) 2014-08-29 2017-07-18 Tes Pharma S.R.L. Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
US10513499B2 (en) 2014-08-29 2019-12-24 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2017182464A1 (en) 2016-04-19 2017-10-26 Cidqo 2012, S.L. New aza- tetracyclo derivatives
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
WO2020167706A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2021026047A1 (en) 2019-08-08 2021-02-11 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
CN111620837A (en) * 2020-06-29 2020-09-04 郑州大学 Cedar ketone thiazole amide compound, and preparation method and application thereof
WO2022040070A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Bicycloheptane pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
CN1438997A (en) 2003-08-27
ZA200209364B (en) 2004-02-18
EP1283834A1 (en) 2003-02-19
EP1283833A1 (en) 2003-02-19
KR20030016272A (en) 2003-02-26
HUP0302435A2 (en) 2003-12-29
CA2408144C (en) 2009-11-24
AR033534A1 (en) 2003-12-26
NO20025586L (en) 2003-01-21
US20100113435A1 (en) 2010-05-06
AU6093101A (en) 2001-12-03
HUP0302435A3 (en) 2007-05-02
CA2409697C (en) 2010-07-13
EA005274B1 (en) 2004-12-30
AU2001262830A1 (en) 2001-12-03
ATE443055T1 (en) 2009-10-15
US20060160797A1 (en) 2006-07-20
CA2408144A1 (en) 2001-11-29
EP1283831A1 (en) 2003-02-19
WO2001090091A8 (en) 2002-07-25
IL152753A0 (en) 2003-06-24
US20060287374A1 (en) 2006-12-21
WO2001090092A1 (en) 2001-11-29
US7132436B2 (en) 2006-11-07
NO20025587L (en) 2003-01-21
JP2003534338A (en) 2003-11-18
BR0111099A (en) 2003-04-15
PL360137A1 (en) 2004-09-06
US7125900B2 (en) 2006-10-24
CN1249039C (en) 2006-04-05
NZ522591A (en) 2004-09-24
NZ522506A (en) 2004-08-27
US20030166689A1 (en) 2003-09-04
WO2001090093A1 (en) 2001-11-29
NO20025586D0 (en) 2002-11-21
NZ522538A (en) 2004-09-24
IL152670A0 (en) 2003-06-24
ATE485283T1 (en) 2010-11-15
US7618961B2 (en) 2009-11-17
NO323779B1 (en) 2007-07-02
CA2408142A1 (en) 2001-11-29
CN1188403C (en) 2005-02-09
US20030176476A1 (en) 2003-09-18
JP2003534339A (en) 2003-11-18
NO323831B1 (en) 2007-07-09
IL152669A0 (en) 2003-06-24
CA2409697A1 (en) 2001-11-29
NO323832B1 (en) 2007-07-09
ZA200209362B (en) 2004-02-18
CN1437588A (en) 2003-08-20
SE0001899D0 (en) 2000-05-22
AU6093201A (en) 2001-12-03
EA200201271A1 (en) 2003-04-24
DE60143293D1 (en) 2010-12-02
CN1430615A (en) 2003-07-16
CN1430614A (en) 2003-07-16
AU2001262831B2 (en) 2006-12-21
CA2408783A1 (en) 2001-11-29
ZA200209360B (en) 2004-02-18
AU2001262831B9 (en) 2007-08-09
EP1283832B1 (en) 2010-10-20
HK1056878A1 (en) 2004-03-05
JP2003534336A (en) 2003-11-18
IL152790A0 (en) 2003-06-24
US20040224996A1 (en) 2004-11-11
NO20025585D0 (en) 2002-11-21
DE1283831T1 (en) 2003-08-14
MXPA02011632A (en) 2004-05-05
KR20030016271A (en) 2003-02-26
DE60139931D1 (en) 2009-10-29
NO20025585L (en) 2002-12-23
EP1283832A1 (en) 2003-02-19
KR20030016269A (en) 2003-02-26
US20030199501A1 (en) 2003-10-23
PE20020100A1 (en) 2002-02-13
WO2001090090A1 (en) 2001-11-29
WO2001090094A1 (en) 2001-11-29
NO20025588D0 (en) 2002-11-21
ES2333846T3 (en) 2010-03-02
CA2408142C (en) 2009-10-20
NO20025588L (en) 2002-12-20
KR20030011341A (en) 2003-02-07
NZ522507A (en) 2004-11-26
US7030135B2 (en) 2006-04-18
ZA200209359B (en) 2004-02-18
AU6283101A (en) 2001-12-03
EP1283834B1 (en) 2009-09-16
NO20025587D0 (en) 2002-11-21
AU6445601A (en) 2001-12-03
JP2003534337A (en) 2003-11-18

Similar Documents

Publication Publication Date Title
US7125900B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP1461325B1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001262831A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7671051B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
AU2001264456B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001264456A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001260932B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001260932A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2007205749A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 152670

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2408142

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 522507

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001264456

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/09359

Country of ref document: ZA

Ref document number: 200209359

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2001938885

Country of ref document: EP

Ref document number: 1020027015741

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018099793

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/2016/CHE

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 1020027015741

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10276954

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001938885

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 522507

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 522507

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2001264456

Country of ref document: AU